Code,Country,Study,Submission,Documents,Note,Date
AT,Austria,Pre-Market,CA,Application Form ,Download from webpage: https://applicationform.basg.gv.at/mpgform/faces/main. In PDF (signed electronically or scanned signed original) and XML ,2022-06-30
AT,Austria,Pre-Market,CA,CIP,With version number and date; compiled according to EN ISO 14155,2022-06-30
AT,Austria,Pre-Market,CA,IB,,2022-06-30
AT,Austria,Pre-Market,CA,IFU,German ,2022-06-30
AT,Austria,Pre-Market,CA,Favorable opinion of the EC,,2022-06-30
AT,Austria,Pre-Market,CA,Patient information and ICF,,2022-06-30
AT,Austria,Pre-Market,CA,Insurance coverage,,2022-06-30
AT,Austria,Pre-Market,CA,Written confirmation that the medical device complies with the essential requirements of the applicable Directive in all aspects except those that will be assessed in the CI,Directive 93/42/EEC Annex I &  Directive 90/385/EEC Annex 1,2022-06-30
AT,Austria,Pre-Market,CA,Declaration of conformity of the manufacturer,,2022-06-30
AT,Austria,Pre-Market,CA,CE marking certificate,,2022-06-30
AT,Austria,Pre-Market,CA,"PI CVs, GCPs",Dated and signed,2022-06-30
AT,Austria,Pre-Market,CA,"Written agreements between the sponsor, monitor, and clinical investigator establishing each party’s responsibilities",,2022-06-30
AT,Austria,Pre-Market,CA,CRF,,2022-06-30
AT,Austria,Pre-Market,CA,"Information on the construction and manufacture of the device, especially sterilisation",,2022-06-30
AT,Austria,Pre-Market,CA,"Results of construction calculations, assessments, technical tests, etc.",,2022-06-30
AT,Austria,Pre-Market,CA,Results of the risk analysis,"Risk analysis, risk minimisation measures See EN ISO 14971",2022-06-30
AT,Austria,Post-Market,CA,Application Form ,Download from webpage: https://applicationform.basg.gv.at/mpgform/faces/main. In PDF (signed electronically or scanned signed original) and XML ,2022-06-30
AT,Austria,Post-Market,CA,CIP,With version number and date; compiled according to EN ISO 14155,2022-06-30
AT,Austria,Post-Market,CA,IB,,2022-06-30
AT,Austria,Post-Market,CA,IFU,German ,2022-06-30
AT,Austria,Post-Market,CA,Favorable opinion of the EC,,2022-06-30
AT,Austria,Post-Market,CA,Patient information and ICF,,2022-06-30
AT,Austria,Post-Market,CA,Insurance coverage,,2022-06-30
AT,Austria,Post-Market,CA,Written confirmation that the medical device complies with the essential requirements of the applicable Directive in all aspects except those that will be assessed in the CI,Directive 93/42/EEC Annex I &  Directive 90/385/EEC Annex 1,2022-06-30
AT,Austria,Post-Market,CA,Declaration of conformity of the manufacturer,,2022-06-30
AT,Austria,Post-Market,CA,CE marking certificate,,2022-06-30
AT,Austria,Post-Market,CA,"PI CVs, GCPs",Dated and signed,2022-06-30
AT,Austria,Post-Market,CA,"Written agreements between the sponsor, monitor, and clinical investigator establishing each party’s responsibilities",,2022-06-30
AT,Austria,Post-Market,CA,CRF,,2022-06-30
AT,Austria,Post-Market,CA,"Information on the construction and manufacture of the device, especially sterilisation",,2022-06-30
AT,Austria,Post-Market,CA,"Results of construction calculations, assessments, technical tests, etc.",,2022-06-30
AT,Austria,Post-Market,CA,Results of the risk analysis,"Risk analysis, risk minimisation measures See EN ISO 14971",2022-06-30
BY,Belarus,Pre-Market,CA,Register the device in the national system,Download form on webpgae. https://rceth.by/ru/Documents/Med/1 ,2022-06-30
BY,Belarus,Pre-Market,CA,Guide for researcher= IB,,2022-06-30
BY,Belarus,Pre-Market,CA,Protocol & amendments ,Dated and signed,2022-06-30
BY,Belarus,Pre-Market,CA,ICF in local language,,2022-06-30
BY,Belarus,Pre-Market,CA,Subjects recruiment,,2022-06-30
BY,Belarus,Pre-Market,CA,Documents on the financial aspect,,2022-06-30
BY,Belarus,Pre-Market,CA,Proof of Insurance,,2022-06-30
BY,Belarus,Pre-Market,CA,Agreement between the parties,,2022-06-30
BY,Belarus,Pre-Market,CA,Permission to conduct a clinical trial,,2022-06-30
BY,Belarus,Pre-Market,CA,"PI & other staffs Cvs, GCPs",,2022-06-30
BY,Belarus,Pre-Market,CA,IFU ,,2022-06-30
BY,Belarus,Pre-Market,CA,Invoices (postal receipts) for the supply of the investigated medical device and medical equipment,,2022-06-30
BY,Belarus,Pre-Market,CA,Other documentations approve by the EC,,2022-06-30
BY,Belarus,Post-Market,CA,Register the device in the national system,Download form on webpgae. https://rceth.by/ru/Documents/Med/1 ,2022-06-30
BY,Belarus,Post-Market,CA,Guide for researcher= IB,,2022-06-30
BY,Belarus,Post-Market,CA,Protocol & amendments ,Dated and signed,2022-06-30
BY,Belarus,Post-Market,CA,ICF in local language,,2022-06-30
BY,Belarus,Post-Market,CA,Subjects recruiment,,2022-06-30
BY,Belarus,Post-Market,CA,Documents on the financial aspect,,2022-06-30
BY,Belarus,Post-Market,CA,Proof of Insurance,,2022-06-30
BY,Belarus,Post-Market,CA,Agreement between the parties,,2022-06-30
BY,Belarus,Post-Market,CA,Permission to conduct a clinical trial,,2022-06-30
BY,Belarus,Post-Market,CA,"PI & other staffs Cvs, GCPs",,2022-06-30
BY,Belarus,Post-Market,CA,IFU ,,2022-06-30
BY,Belarus,Post-Market,CA,Invoices (postal receipts) for the supply of the investigated medical device and medical equipment,,2022-06-30
BY,Belarus,Post-Market,CA,Other documentations approve by the EC,,2022-06-30
BE,Belgium,Pre-Market,CA,COVER LETTER,It should be clearly mentioned which Belgian regulatory pathway is applicable: Consolidated opinion FAMHP and EC ,2022-06-30
BE,Belgium,Pre-Market,CA,List of documents submitted ,Template on website,2022-06-30
BE,Belgium,Pre-Market,CA,APPLICATION FORM,Template on website,2022-06-30
BE,Belgium,Pre-Market,CA,"CIP (with Annexes, version and date)",,2022-06-30
BE,Belgium,Pre-Market,CA,Synopsis,,2022-06-30
BE,Belgium,Pre-Market,CA,INVESTIGATOR’S BROCHURE (With annexes),,2022-06-30
BE,Belgium,Pre-Market,CA,Example of labels,,2022-06-30
BE,Belgium,Pre-Market,CA,LIST OF GENERAL SAFETY AND PERFORMANCE REQUIREMENTS,Template on website,2022-06-30
BE,Belgium,Pre-Market,CA,MANUFACTURER’S IFU,,2022-06-30
BE,Belgium,Pre-Market,CA,CLINICAL EVALUATION PLAN,,2022-06-30
BE,Belgium,Pre-Market,CA,PROOF OF INSURANCE,,2022-06-30
BE,Belgium,Pre-Market,CA,"PI Cvs, GCPs, & DOI ",,2022-06-30
BE,Belgium,Pre-Market,CA,SUITABILITY OF SITE(S),,2022-06-30
BE,Belgium,Pre-Market,CA,Agreements between parties,,2022-06-30
BE,Belgium,Pre-Market,CA,RECRUITMENT AND ADVERTISING,,2022-06-30
BE,Belgium,Pre-Market,CA,"PATIENT INFO, ICF AND ICF PROCEDURE",,2022-06-30
BE,Belgium,Pre-Market,CA,FINANCIAL AND OTHER ARRANGEMENTS,,2022-06-30
BE,Belgium,Pre-Market,CA,STATEMENT ON DATA PROTECTION,,2022-06-30
BE,Belgium,Pre-Market,CA,"If multinational, status on submission procedure(s) in other countries, including any approval or refusal letter if applicable.",,2022-06-30
BE,Belgium,Pre-Market,CA,CE certificate and manufacturer’s instructions for use of any comparator device used,,2022-06-30
BG,Bulgaria,Pre-Market,CA,Cover Letter ,,2022-06-30
BG,Bulgaria,Pre-Market,CA,Medical device identification data on paper & electronic carrier,,2022-06-30
BG,Bulgaria,Pre-Market,CA,Clinical investigation plan (CIP),"Contain purpose, scientific, technical and medical reasons for conduction, scope, methodology and organization of investigation and number of devices",2022-06-30
BG,Bulgaria,Pre-Market,CA,"PI Cvs, GCPs",,2022-06-30
BG,Bulgaria,Pre-Market,CA,Centres list,Name & address ,2022-06-30
BG,Bulgaria,Pre-Market,CA,IB,,2022-06-30
BG,Bulgaria,Pre-Market,CA,ICF & Patient information,,2022-06-30
BG,Bulgaria,Pre-Market,CA,Declaration by the manufacturer whether the device to be tested can be defined as a device," according the Art. 3, pp. 2, 3 or 4 of MDL",2022-06-30
BG,Bulgaria,Pre-Market,CA,Start and end date and schedule of investigation,,2022-06-30
BG,Bulgaria,Pre-Market,CA,Positive statement of Ethics Committee,submission to EC before,2022-06-30
BG,Bulgaria,Pre-Market,CA,"Declaration, that medical device is in conformity with essential requirement",,2022-06-30
BG,Bulgaria,Pre-Market,CA,Proof of insurance,,2022-06-30
BG,Bulgaria,Pre-Market,CA,Contracts between parties,,2022-06-30
BG,Bulgaria,Pre-Market,CA,Receipt of payment,Medical device law,2022-06-30
BG,Bulgaria,Post-Market,CA,Cover Letter ,,2022-06-30
BG,Bulgaria,Post-Market,CA,Medical device identification data on paper & electronic carrier,,2022-06-30
BG,Bulgaria,Post-Market,CA,Clinical investigation plan (CIP),"Contain purpose, scientific, technical and medical reasons for conduction, scope, methodology and organization of investigation and number of devices",2022-06-30
BG,Bulgaria,Post-Market,CA,"PI Cvs, GCPs",,2022-06-30
BG,Bulgaria,Post-Market,CA,Centres list,Name & address ,2022-06-30
BG,Bulgaria,Post-Market,CA,IB,,2022-06-30
BG,Bulgaria,Post-Market,CA,ICF & Patient information,,2022-06-30
BG,Bulgaria,Post-Market,CA,Declaration by the manufacturer whether the device to be tested can be defined as a device," according the Art. 3, pp. 2, 3 or 4 of MDL",2022-06-30
BG,Bulgaria,Post-Market,CA,Start and end date and schedule of investigation,,2022-06-30
BG,Bulgaria,Post-Market,CA,Positive statement of Ethics Committee,submission to EC before,2022-06-30
BG,Bulgaria,Post-Market,CA,"Declaration, that medical device is in conformity with essential requirement",,2022-06-30
BG,Bulgaria,Post-Market,CA,Proof of insurance,,2022-06-30
BG,Bulgaria,Post-Market,CA,Contracts between parties,,2022-06-30
BG,Bulgaria,Post-Market,CA,Receipt of payment,Medical device law,2022-06-30
CH,Switzerland,Pre-Market,CA,Authorisation aplication form,Download online ,2022-06-30
CH,Switzerland,Pre-Market,CA,Cover Letter,,2022-06-30
CH,Switzerland,Pre-Market,CA,interim EC opinion,,2022-06-30
CH,Switzerland,Pre-Market,CA,Foreign Competent Authority decision,If aplicable,2022-06-30
CH,Switzerland,Pre-Market,CA,CIP,,2022-06-30
CH,Switzerland,Pre-Market,CA,CRF,,2022-06-30
CH,Switzerland,Pre-Market,CA,ICF & patient information sheet,,2022-06-30
CH,Switzerland,Pre-Market,CA,Compliance with ISO 14155,,2022-06-30
CH,Switzerland,Pre-Market,CA,Up to date IB,,2022-06-30
CH,Switzerland,Pre-Market,CA,"IFU, if not integrated in IB",,2022-06-30
CH,Switzerland,Pre-Market,CA,Matrix of general safety and performance requirements and list of applicable standards,,2022-06-30
CH,Switzerland,Pre-Market,CA,"Confirmation that the documentation is being kept available in accordance with chapter III of Annex XV of the MDR for at least 10 years, 15 years in case of implants",,2022-06-30
CH,Switzerland,Pre-Market,CA,Proof of insurance,,2022-06-30
CH,Switzerland,Pre-Market,CA,Animal origin information ,If aplicable,2022-06-30
CH,Switzerland,Pre-Market,CA,MRI checklist,If aplicable,2022-06-30
CH,Switzerland,Pre-Market,CA,Ionising radiation information,If aplicable,2022-06-30
CH,Switzerland,Pre-Market,CA,Contract between Sponsor & manufacturer (if not the same one),,2022-06-30
CH,Switzerland,Pre-Market,CA,Trial center lists,Both in Switzerland and abroad,2022-06-30
CH,Switzerland,Pre-Market,CA,"PI CVs, GCPs; ",,2022-06-30
CH,Switzerland,Pre-Market,CA,"NOTE: the maximum file size should not exceed 200MB per PDF file. Larger files must be split. Documents formats: PDF, Excel & scanned documents. ",,2022-06-30
CH,Switzerland,Post-Market,CA,"NO NEED TO SUBMIT TO CA, EC ONLY. Category A clinical trials",,2022-06-30
CR,Costa Rica,Pre-Market,CA,Instruction,The data entered into the SEP Online database and the data submitted to the Agency in hard copy must be identical. See EC submission. ,2022-06-30
CR,Costa Rica,Post-Market,CA,Instruction,The data entered into the SEP Online database and the data submitted to the Agency in hard copy must be identical. See EC submission. ,2022-06-30
CY,Cyprus,Pre-Market,CA,Aplication form ,Download from webpage,2022-06-30
CY,Cyprus,Pre-Market,CA,A copy of the opinion of the Cyprus National Ethics Committee,,2022-06-30
CY,Cyprus,Pre-Market,CA,Data allowing identification of the device,"(i) Generic Name (ii) Model name (iii) Model Number (i.e. Label, Instruction for Use).",2022-06-30
CY,Cyprus,Pre-Market,CA,A general description of the product  ,,2022-06-30
CY,Cyprus,Pre-Market,CA,CIP,,2022-06-30
CY,Cyprus,Pre-Market,CA,Criteria of patient selection,,2022-06-30
CY,Cyprus,Pre-Market,CA,Number of patient in clinical investigation,,2022-06-30
CY,Cyprus,Pre-Market,CA,"Design drawings and methods of manufacture envisaged, in particular as regards sterilization and diagrams of components, sub assemblies, circuits etc.",May not be submitted but must be available in case the CA wants.,2022-06-30
CY,Cyprus,Pre-Market,CA,The results of the risk analysis & GSPRs analysis,,2022-06-30
CY,Cyprus,Pre-Market,CA,The results of the design calculation and of the inspections and technical tests carried out ,,2022-06-30
CY,Cyprus,Pre-Market,CA,"Summary of the experience with any similar device manufactured, including length of time on the market and a review of performance related complaints ",,2022-06-30
CY,Cyprus,Pre-Market,CA,"Details of new or previously untested features of the device including where applicable, functions and principles of operation",,2022-06-30
CY,Cyprus,Pre-Market,CA,Image of the device ,,2022-06-30
CY,Cyprus,Post-Market,CA,Aplication form ,Download from webpage,2022-06-30
CY,Cyprus,Post-Market,CA,A copy of the opinion of the Cyprus National Ethics Committee,,2022-06-30
CY,Cyprus,Post-Market,CA,Data allowing identification of the device,"(i) Generic Name (ii) Model name (iii) Model Number (i.e. Label, Instruction for Use).",2022-06-30
CY,Cyprus,Post-Market,CA,A general description of the product  ,,2022-06-30
CY,Cyprus,Post-Market,CA,CIP,,2022-06-30
CY,Cyprus,Post-Market,CA,Criteria of patient selection,,2022-06-30
CY,Cyprus,Post-Market,CA,Number of patient in clinical investigation,,2022-06-30
CY,Cyprus,Post-Market,CA,"Design drawings and methods of manufacture envisaged, in particular as regards sterilization and diagrams of components, sub assemblies, circuits etc.",May not be submitted but must be available in case the CA wants.,2022-06-30
CY,Cyprus,Post-Market,CA,The results of the risk analysis & GSPRs analysis,,2022-06-30
CY,Cyprus,Post-Market,CA,The results of the design calculation and of the inspections and technical tests carried out ,,2022-06-30
CY,Cyprus,Post-Market,CA,"Summary of the experience with any similar device manufactured, including length of time on the market and a review of performance related complaints ",,2022-06-30
CY,Cyprus,Post-Market,CA,"Details of new or previously untested features of the device including where applicable, functions and principles of operation",,2022-06-30
CY,Cyprus,Post-Market,CA,Image of the device ,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Investigator's Brochure IB,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,CIP,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Approval of the EC,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,ICF ,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Insurance information,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,A declaration to the effect whether the medical device contains an active substance or a human blood or plasma derivative as its integral part (if aplicable),,2022-06-30
CZ,Czech Republic,Pre-Market,CA,A declaration to the effect whether the medical device has been manufactured using tissues of animal origin with a view to the minimisation of risk of transfer of TSE infection to man,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,A declaration to the effect that the concerned medical device meets the basic requirements governing medical devices in conformity assessment,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Label of investigational medical device (in English or in Czech),,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Extra information,The sponsors established outside the territory of the Czech Republic are highly recommended to consider cooperation with CROs established in the Czech Republic. Such cooperation might contribute to speeding up the processing of applications,2022-06-30
CZ,Czech Republic,Post-Market,CA,Investigator's Brochure IB,,2022-06-30
CZ,Czech Republic,Post-Market,CA,CIP,,2022-06-30
CZ,Czech Republic,Post-Market,CA,Approval of the EC,,2022-06-30
CZ,Czech Republic,Post-Market,CA,ICF ,,2022-06-30
CZ,Czech Republic,Post-Market,CA,Insurance information,,2022-06-30
CZ,Czech Republic,Post-Market,CA,A declaration to the effect whether the medical device contains an active substance or a human blood or plasma derivative as its integral part (if aplicable),,2022-06-30
CZ,Czech Republic,Post-Market,CA,A declaration to the effect whether the medical device has been manufactured using tissues of animal origin with a view to the minimisation of risk of transfer of TSE infection to man,,2022-06-30
CZ,Czech Republic,Post-Market,CA,A declaration to the effect that the concerned medical device meets the basic requirements governing medical devices in conformity assessment,,2022-06-30
CZ,Czech Republic,Post-Market,CA,Label of investigational medical device (in English or in Czech),,2022-06-30
CZ,Czech Republic,Post-Market,CA,Extra information,The sponsors established outside the territory of the Czech Republic are highly recommended to consider cooperation with CROs established in the Czech Republic. Such cooperation might contribute to speeding up the processing of applications,2022-06-30
DK,Denmark,Pre-Market,CA,SAME TO BOTH EC & CA,,2022-06-30
DK,Denmark,Pre-Market,CA,“01.01 Cover letter”,,2022-06-30
DK,Denmark,Pre-Market,CA,“01.02 Application form”,,2022-06-30
DK,Denmark,Pre-Market,CA,“02.01 Investigator Brocure”,,2022-06-30
DK,Denmark,Pre-Market,CA,“02.02 Instruction for use”,,2022-06-30
DK,Denmark,Pre-Market,CA,“02.03 Checklist for fulfilment of general safety performance requirements”,,2022-06-30
DK,Denmark,Pre-Market,CA,“03.01 Clinical investigation plan”,,2022-06-30
DK,Denmark,Pre-Market,CA,Patient information(s) and informed consent form(s),“04.01 Subject information and consent form patients”                                                                           “04.02 Subject information and consent form legal representative”; 04.03 and so on ,2022-06-30
DK,Denmark,Pre-Market,CA,Statement certifying that the device in question complies with the General safety and performance requirements,“05.01 Statement of compliance”,2022-06-30
DK,Denmark,Pre-Market,CA,CE certificate ,“05.02 Declaration of conformity”,2022-06-30
DK,Denmark,Pre-Market,CA,GDPR Data protection ,“06.01 sponsors statement on how to comply with GDPR”; 06.02… ,2022-06-30
DK,Denmark,Pre-Market,CA,Extra information (See note),Send documents to both EC & CA. ,2022-06-30
DK,Denmark,Pre-Market,CA,REQUIRED FROM EC,SEE EC EXCEL ,2022-06-30
DK,Denmark,Post-Market,CA,SAME TO BOTH EC & CA,ONLY SEND IF THE MD IS INVASIVE OR BURDENSOME,2022-06-30
DK,Denmark,Post-Market,CA,“01.01 Cover letter”,,2022-06-30
DK,Denmark,Post-Market,CA,“01.02 Application form”,,2022-06-30
DK,Denmark,Post-Market,CA,“02.01 Investigator Brocure”,,2022-06-30
DK,Denmark,Post-Market,CA,“02.02 Instruction for use”,,2022-06-30
DK,Denmark,Post-Market,CA,“02.03 Checklist for fulfilment of general safety performance requirements”,,2022-06-30
DK,Denmark,Post-Market,CA,“03.01 Clinical investigation plan”,,2022-06-30
DK,Denmark,Post-Market,CA,Patient information(s) and informed consent form(s),“04.01 Subject information and consent form patients”                                                                           “04.02 Subject information and consent form legal representative”; 04.03 and so on ,2022-06-30
DK,Denmark,Post-Market,CA,Statement certifying that the device in question complies with the General safety and performance requirements,“05.01 Statement of compliance”,2022-06-30
DK,Denmark,Post-Market,CA,CE certificate ,“05.02 Declaration of conformity”,2022-06-30
DK,Denmark,Post-Market,CA,GDPR Data protection ,“06.01 sponsors statement on how to comply with GDPR”; 06.02… ,2022-06-30
DK,Denmark,Post-Market,CA,Extra information (See note),Send documents to both EC & CA. ,2022-06-30
DK,Denmark,Post-Market,CA,REQUIRED FROM EC,SEE EC EXCEL ,2022-06-30
DE,Germany,Pre-Market,CA,Cover Letter,,2022-06-30
DE,Germany,Pre-Market,CA,Aplication Form,,2022-06-30
DE,Germany,Pre-Market,CA,IB,,2022-06-30
DE,Germany,Pre-Market,CA,CIP ,"Version, dated and signed",2022-06-30
DE,Germany,Pre-Market,CA,Statement from sponsor of fulfilling the GSPRs,,2022-06-30
DE,Germany,Pre-Market,CA,Opinion of the EC,,2022-06-30
DE,Germany,Pre-Market,CA,Proof of insurance,,2022-06-30
DE,Germany,Pre-Market,CA,ICF,,2022-06-30
DE,Germany,Pre-Market,CA,Data protection,,2022-06-30
DE,Germany,Pre-Market,CA,Technical documentatiins of the device,,2022-06-30
DE,Germany,Post-Market,CA,"Note: If the clinical investigation is with a CE-marked medical device, within its intended purpose, is not exposed to any additional invasive or burdensome procedure → EC ONLY.",Looking for the local EC for more informtion. ,2022-06-30
DE,Germany,Post-Market,CA,"Other cases: undergoing additional invasive or burdensome procedures, or use outside intended purpose → Full submission same as pre- market ",,2022-06-30
EE,Estonia,Pre-Market,CA,MANDATORY,,2022-06-30
EE,Estonia,Pre-Market,CA,Cover Letter,,2022-06-30
EE,Estonia,Pre-Market,CA,Aplication Form ,Download from web,2022-06-30
EE,Estonia,Pre-Market,CA,IB,Including annexes ,2022-06-30
EE,Estonia,Pre-Market,CA,CIP,,2022-06-30
EE,Estonia,Pre-Market,CA,CEP,,2022-06-30
EE,Estonia,Pre-Market,CA,Synopsis,,2022-06-30
EE,Estonia,Pre-Market,CA,Statement of conformity,,2022-06-30
EE,Estonia,Pre-Market,CA,Example of labels,,2022-06-30
EE,Estonia,Pre-Market,CA,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,,2022-06-30
EE,Estonia,Pre-Market,CA,List of GSPRs ,,2022-06-30
EE,Estonia,Pre-Market,CA,AS APLICABLE,,2022-06-30
EE,Estonia,Pre-Market,CA,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,,2022-06-30
EE,Estonia,Pre-Market,CA,Risk management,,2022-06-30
EE,Estonia,Pre-Market,CA,Test reports,,2022-06-30
EE,Estonia,Pre-Market,CA,Proof of clinical Insurance,,2022-06-30
EE,Estonia,Pre-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
EE,Estonia,Pre-Market,CA,Manufacturer's IFU,,2022-06-30
EE,Estonia,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
EE,Estonia,Pre-Market,CA,Recruitment procedures,,2022-06-30
EE,Estonia,Pre-Market,CA,ICF & related documentation,,2022-06-30
EE,Estonia,Pre-Market,CA,Decisions from other countries,,2022-06-30
EE,Estonia,Pre-Market,CA,Receipt of state fee,"Beneficiary's name: Ministry of Finance
Account:
SEB Pank EE891010220034796011 (BIC / SWIFT: EEUHEE2X)
Swedbank EE932200221023778606 (BIC / SWIFT: HABAEE2X)
LHV Bank EE777700771003813400 (BIC / SWIFT: LHVBEE22)
Luminor Bank EE701700017001577198 (BIC / SWIFT: NDEAEE2X)

Reference number: 2900083031

 NB! The reference number is mandatory on bank transfer!",2022-06-30
EE,Estonia,Post-Market,CA,MANDATORY,,2022-06-30
EE,Estonia,Post-Market,CA,Cover Letter,,2022-06-30
EE,Estonia,Post-Market,CA,Aplication Form ,Download from web,2022-06-30
EE,Estonia,Post-Market,CA,IB,Including annexes ,2022-06-30
EE,Estonia,Post-Market,CA,CIP,,2022-06-30
EE,Estonia,Post-Market,CA,CEP,,2022-06-30
EE,Estonia,Post-Market,CA,Synopsis,,2022-06-30
EE,Estonia,Post-Market,CA,Statement of conformity,,2022-06-30
EE,Estonia,Post-Market,CA,Example of labels,,2022-06-30
EE,Estonia,Post-Market,CA,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,,2022-06-30
EE,Estonia,Post-Market,CA,List of GSPRs ,,2022-06-30
EE,Estonia,Post-Market,CA,AS APLICABLE,,2022-06-30
EE,Estonia,Post-Market,CA,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,,2022-06-30
EE,Estonia,Post-Market,CA,Risk management,,2022-06-30
EE,Estonia,Post-Market,CA,Test reports,,2022-06-30
EE,Estonia,Post-Market,CA,Proof of clinical Insurance,,2022-06-30
EE,Estonia,Post-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
EE,Estonia,Post-Market,CA,Manufacturer's IFU,,2022-06-30
EE,Estonia,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
EE,Estonia,Post-Market,CA,Recruitment procedures,,2022-06-30
EE,Estonia,Post-Market,CA,ICF & related documentation,,2022-06-30
EE,Estonia,Post-Market,CA,CE certificate,,2022-06-30
EE,Estonia,Post-Market,CA,Decisions from other countries,,2022-06-30
EE,Estonia,Post-Market,CA,PMCF Plan,,2022-06-30
EE,Estonia,Post-Market,CA,Receipt of state fee,"Beneficiary's name: Ministry of Finance
Account:
SEB Pank EE891010220034796011 (BIC / SWIFT: EEUHEE2X)
Swedbank EE932200221023778606 (BIC / SWIFT: HABAEE2X)
LHV Bank EE777700771003813400 (BIC / SWIFT: LHVBEE22)
Luminor Bank EE701700017001577198 (BIC / SWIFT: NDEAEE2X)

Reference number: 2900083031

 NB! The reference number is mandatory on bank transfer!",2022-06-30
ES,Spain,Pre-Market,CA,Cover Letter ,,2022-06-30
ES,Spain,Pre-Market,CA,Aplication Form ,,2022-06-30
ES,Spain,Pre-Market,CA,sponsor’s and manufacturer’s name & contact form,,2022-06-30
ES,Spain,Pre-Market,CA,Specify that It is the first submission,,2022-06-30
ES,Spain,Pre-Market,CA,All countries participants (if multicenter/nationals study),,2022-06-30
ES,Spain,Pre-Market,CA,EUDAMED ID (CIV ID),,2022-06-30
ES,Spain,Pre-Market,CA,EC opinion (asap),,2022-06-30
ES,Spain,Pre-Market,CA,CE mark certification,,2022-06-30
ES,Spain,Pre-Market,CA,CIP,,2022-06-30
ES,Spain,Pre-Market,CA,IB,,2022-06-30
ES,Spain,Pre-Market,CA,Proof of Insurance ,,2022-06-30
ES,Spain,Pre-Market,CA,ICF & Patient information documents,,2022-06-30
ES,Spain,Pre-Market,CA,"a statement indicating whether or not the device incorporates, as an integral part, a substance or human blood derivative referred to in Section 10 of Annex 1 of Directive 90/385/EEC respectively section 7.4 of Annex I of Directive 93/42/EEC;",,2022-06-30
ES,Spain,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
ES,Spain,Post-Market,CA,EC favorable responds,,2022-06-30
ES,Spain,Post-Market,CA,CE certification,,2022-06-30
ES,Spain,Post-Market,CA,CIP in Spanish,,2022-06-30
ES,Spain,Post-Market,CA,IFU in Spanish,,2022-06-30
FI,Finland,Pre-Market,CA,MANDATORY,,2022-06-30
FI,Finland,Pre-Market,CA,Cover letter,,2022-06-30
FI,Finland,Pre-Market,CA,Application form,,2022-06-30
FI,Finland,Pre-Market,CA,Investigator’s Brochure (including any annexes) ,,2022-06-30
FI,Finland,Pre-Market,CA,CIP,,2022-06-30
FI,Finland,Pre-Market,CA,CEP,,2022-06-30
FI,Finland,Pre-Market,CA,Synopsis,,2022-06-30
FI,Finland,Pre-Market,CA,Statement of conformity,,2022-06-30
FI,Finland,Pre-Market,CA,Example of labels,,2022-06-30
FI,Finland,Pre-Market,CA,The protection and confidentiality of personal data/ personal information,,2022-06-30
FI,Finland,Pre-Market,CA,List of GSPRs,,2022-06-30
FI,Finland,Pre-Market,CA,AS APLICABLE,,2022-06-30
FI,Finland,Pre-Market,CA,Risk management documentation,,2022-06-30
FI,Finland,Pre-Market,CA,Test reports,,2022-06-30
FI,Finland,Pre-Market,CA,Proof of Clinical Investigation Insurance,,2022-06-30
FI,Finland,Pre-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
FI,Finland,Pre-Market,CA,Manufacturer’s Instructions for Use,,2022-06-30
FI,Finland,Pre-Market,CA,Suitability of the investigators,,2022-06-30
FI,Finland,Pre-Market,CA,Recruitment procedures and advertising materials,,2022-06-30
FI,Finland,Pre-Market,CA,"ICF, participants information, compensation….",,2022-06-30
FI,Finland,Pre-Market,CA,Decisions from other countries,,2022-06-30
FI,Finland,Post-Market,CA,MANDATORY,,2022-06-30
FI,Finland,Post-Market,CA,Cover letter,,2022-06-30
FI,Finland,Post-Market,CA,Application form,,2022-06-30
FI,Finland,Post-Market,CA,Investigator’s Brochure (including any annexes) ,,2022-06-30
FI,Finland,Post-Market,CA,CIP,,2022-06-30
FI,Finland,Post-Market,CA,CEP,,2022-06-30
FI,Finland,Post-Market,CA,Synopsis,,2022-06-30
FI,Finland,Post-Market,CA,Statement of conformity,,2022-06-30
FI,Finland,Post-Market,CA,Example of labels,,2022-06-30
FI,Finland,Post-Market,CA,The protection and confidentiality of personal data/ personal information,,2022-06-30
FI,Finland,Post-Market,CA,List of GSPRs,,2022-06-30
FI,Finland,Post-Market,CA,AS APLICABLE,,2022-06-30
FI,Finland,Post-Market,CA,Risk management documentation,,2022-06-30
FI,Finland,Post-Market,CA,Test reports,,2022-06-30
FI,Finland,Post-Market,CA,Proof of Clinical Investigation Insurance,,2022-06-30
FI,Finland,Post-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
FI,Finland,Post-Market,CA,Manufacturer’s Instructions for Use,,2022-06-30
FI,Finland,Post-Market,CA,Suitability of the investigators,,2022-06-30
FI,Finland,Post-Market,CA,Recruitment procedures and advertising materials,,2022-06-30
FI,Finland,Post-Market,CA,"ICF, participants information, compensation….",,2022-06-30
FI,Finland,Post-Market,CA,CE Certificate,,2022-06-30
FI,Finland,Post-Market,CA,Decisions from other countries,,2022-06-30
FI,Finland,Post-Market,CA,PMCF Plan,,2022-06-30
FR,France,Pre-Market,CA,Main,,2022-06-30
FR,France,Pre-Market,CA,Application form (FAEC) ,Please refer to Annex 2 of AAP-part 2,2022-06-30
FR,France,Pre-Market,CA,Clinical evaluation plan (CEP),summary of the clinical evaluation plan (precise Version number and Date),2022-06-30
FR,France,Pre-Market,CA,Investigator brochure (IB),(precise version number and date),2022-06-30
FR,France,Pre-Market,CA,Clinical investigation plan (PROTOCOLE),Containing all items of annex XV chap II.3 (precise Version number and Date),2022-06-30
FR,France,Pre-Market,CA,Protocol synopsis (RESUME),French,2022-06-30
FR,France,Pre-Market,CA,Other information (Please refer to Annex XV chap II 4),,2022-06-30
FR,France,Pre-Market,CA,"Signed statement by the natural or legal person responsible for the manufacture of the investigational device in question that it conforms to the general safety and performance requirements apart from the aspects covered by the clinical investigation and that, with regards to those aspects, every precaution has been taken to protect the health and safety of the subject",,2022-06-30
FR,France,Pre-Market,CA,Signed statement that the sponsor is aware that the competent authority may contact the ethics committee that is assessing or has assessed the application,,2022-06-30
FR,France,Pre-Market,CA,Proof of insurance (ASSURANCE) cover or indemnification of subjects in case of injury,"The proof of insurance cover must comply with the articles L. 1121-10 and 
R.1121-4 to R1121-9 of the French public health code. It must cover at least 
the period between the first inclusion and the last visit of a French participant. 
It must mention the estimated end date of the study and the contact details 
of the EU legal representative. IN FRENCH",2022-06-30
FR,France,Pre-Market,CA,Documents to be used to obtain informed consent (NIFC),"Please refer to page 7 of AAP-part 2 for details regarding the modalities of 
submission. IN FRENCH",2022-06-30
FR,France,Pre-Market,CA,"Patient Information form (including all written information to participants, and compensation of participants)",In French,2022-06-30
FR,France,Pre-Market,CA,Informed consent sheet,In French,2022-06-30
FR,France,Pre-Market,CA,Informed consent process,In French,2022-06-30
FR,France,Pre-Market,CA,"All the document used to recruit participants (letter to general practitioners, posters, explanatory booklets, websites, etc.) (RECRUTEMENT)",In french,2022-06-30
FR,France,Pre-Market,CA,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information (refer to annex XV chap II 4.5) (DONNEES),Please refer to page 7 of AAP part 2 for details,2022-06-30
FR,France,Pre-Market,CA,Copy of the opinion of the Ethics Committee (CPP) if available (to be submitted as soon as available) (AVIS),if applicable,2022-06-30
FR,France,Pre-Market,CA,Technical file (DOSSIER_TECHNIQUE),,2022-06-30
FR,France,Pre-Market,CA,Instruction for use for the clinical investigation ,Version No & Date,2022-06-30
FR,France,Pre-Market,CA,"Risk management, risk analysis",,2022-06-30
FR,France,Pre-Market,CA,List of standards and common specifications applied (if not included in the IB),(precise Version number and Date),2022-06-30
FR,France,Pre-Market,CA,List of technical and functional features and the related expected clinical outcomes of the studied medical device,,2022-06-30
FR,France,Pre-Market,CA,Critical analysis of non-clinical and clinical data related to the MD studied in relation to the evaluation of the benefits and risks of the investigation,,2022-06-30
FR,France,Pre-Market,CA,Pre-clinical data,,2022-06-30
FR,France,Pre-Market,CA,Clinical data,,2022-06-30
FR,France,Pre-Market,CA,Other documents - National requirements (DOCUMENTS),,2022-06-30
FR,France,Pre-Market,CA,"Investigator list, proof of suitability of clinical investigators (LISTE_CV) and of suitability of investigational sites and investigational site team (EQUIPEMENT) ",Please refer to page 7 of AAP for details regarding the CV,2022-06-30
FR,France,Pre-Market,CA,Authorisation of the investigational site (JUS_EQUIPEMENT),,2022-06-30
FR,France,Pre-Market,CA,Import certificate for investigational medicinal products used in the IC ,If applicable. In French,2022-06-30
FR,France,Pre-Market,CA,Copy of the authorization issued by the third party to the sponsor to communicate the data related to the MD,,2022-06-30
FR,France,Pre-Market,CA,PMCF plan,,2022-06-30
FR,France,Post-Market,CA,Main,,2022-06-30
FR,France,Post-Market,CA,Application form (FAEC) ,Please refer to Annex 2 of AAP-part 2,2022-06-30
FR,France,Post-Market,CA,Clinical evaluation plan (CEP),summary of the clinical evaluation plan (precise Version number and Date),2022-06-30
FR,France,Post-Market,CA,Instruction for use (IFU) for CE medical device used within or without the scope of its intended purpose,(precise version number and date),2022-06-30
FR,France,Post-Market,CA,Clinical investigation plan (PROTOCOLE),Containing all items of annex XV chap II.3 (precise Version number and Date),2022-06-30
FR,France,Post-Market,CA,Protocol synopsis (RESUME),French,2022-06-30
FR,France,Post-Market,CA,Other information (Please refer to Annex XV chap II 4),,2022-06-30
FR,France,Post-Market,CA,Signed statement that the sponsor is aware that the competent authority may contact the ethics committee that is assessing or has assessed the application,,2022-06-30
FR,France,Post-Market,CA,Proof of insurance (ASSURANCE) cover or indemnification of subjects in case of injury,"The proof of insurance cover must comply with the articles L. 1121-10 and 
R.1121-4 to R1121-9 of the French public health code. It must cover at least 
the period between the first inclusion and the last visit of a French participant. 
It must mention the estimated end date of the study and the contact details 
of the EU legal representative. IN FRENCH",2022-06-30
FR,France,Post-Market,CA,Documents to be used to obtain informed consent (NIFC),"Please refer to page 7 of AAP-part 2 for details regarding the modalities of 
submission. IN FRENCH",2022-06-30
FR,France,Post-Market,CA,"Patient Information form (including all written information to participants, and compensation of participants)",In French,2022-06-30
FR,France,Post-Market,CA,Informed consent sheet,In French,2022-06-30
FR,France,Post-Market,CA,Informed consent process,In French,2022-06-30
FR,France,Post-Market,CA,"All the document used to recruit participants (letter to general practitioners, posters, explanatory booklets, websites, etc.) (RECRUTEMENT)",In french,2022-06-30
FR,France,Post-Market,CA,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information (refer to annex XV chap II 4.5) (DONNEES),Please refer to page 7 of AAP part 2 for details,2022-06-30
FR,France,Post-Market,CA,Copy of the opinion of the Ethics Committee (CPP) if available (to be submitted as soon as available) (AVIS),if applicable,2022-06-30
FR,France,Post-Market,CA,Technical file (DOSSIER_TECHNIQUE),,2022-06-30
FR,France,Post-Market,CA,Statement of conformity: EC declaration of conformity or EU declaration of conformity ,(refer to art.19),2022-06-30
FR,France,Post-Market,CA,EC certificate,,2022-06-30
FR,France,Post-Market,CA,Instructions for use for the clinical investigation ,(precise Version number and Date),2022-06-30
FR,France,Post-Market,CA,Other documents - National requirements (DOCUMENTS),,2022-06-30
FR,France,Post-Market,CA,"Investigator list, proof of suitability of clinical investigators (LISTE_CV) and of suitability of investigational sites and investigational site team (EQUIPEMENT) ",Please refer to page 7 of AAP for details regarding the CV,2022-06-30
FR,France,Post-Market,CA,Import certificate for investigational medicinal products used in the IC ,If applicable. In French,2022-06-30
FR,France,Post-Market,CA,PMCF plan,,2022-06-30
GK,Grece,Pre-Market,CA,I. Cover letter containing a list of contents and the total budget of the study in Greece (summary),,2022-06-30
GK,Grece,Pre-Market,CA,"II. General Part: The documentation to be included in the General Part of the filing file to the EOF is set out in Annex XV, Chapter II of Regulation (EU) 2017/745.",,2022-06-30
GK,Grece,Pre-Market,CA,Application Form,,2022-06-30
GK,Grece,Pre-Market,CA,Investigator Brochure (IB),,2022-06-30
GK,Grece,Pre-Market,CA,Clinical Investigation Plan (CIP),,2022-06-30
GK,Grece,Pre-Market,CA,Compliance statement letter,,2022-06-30
GK,Grece,Pre-Market,CA,Insurance certificate,,2022-06-30
GK,Grece,Pre-Market,CA,Patient informed consent form (ICF),,2022-06-30
GK,Grece,Pre-Market,CA,Data confidentiality letter,,2022-06-30
GK,Grece,Pre-Market,CA,Instruction for use (IFU),,2022-06-30
GK,Grece,Pre-Market,CA,Case report form (CRF),,2022-06-30
GK,Grece,Pre-Market,CA,"III. Special Part: In addition to the supporting documents of the General Part, the file to the EOF will include the following Special supporting documents:",,2022-06-30
GK,Grece,Pre-Market,CA,"Completed the application form in Greek (available on the EOF website), in searchable pdf format, with signature, signatory details and date  ",,2022-06-30
GK,Grece,Pre-Market,CA,"General Summary of the clinical investigation plan (SYNOPSIS) in the Greek language (Relative to Section 3.1.5 of Reg. 2017/745, Par. XV, Chapter II)",,2022-06-30
GK,Grece,Pre-Market,CA,"Patient information and consent form (s), in Greek (& original in English if available). ",,2022-06-30
GK,Grece,Pre-Market,CA,Agreement PI & Sponsor,,2022-06-30
GK,Grece,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
GK,Grece,Pre-Market,CA,"If the applicant is not the sponsor, a letter of authorization to the applicant to act on behalf of the sponsor.",,2022-06-30
GK,Grece,Pre-Market,CA,CE marking certificate (if aplicable),,2022-06-30
GK,Grece,Pre-Market,CA,"Model of the label in the Greek language in which there will be, among other information, the labeling ""exclusively for clinical trials"".",,2022-06-30
GK,Grece,Pre-Market,CA,"Responsible statement from the sponsor stating whether the product contains as an integral part of the substance or derivative of human blood (in addition to Point 2.6 of Reg. 2017/745, Par. XV, Chapter II).",,2022-06-30
GK,Grece,Pre-Market,CA,Proof of payment of a fee in favor of EOF,,2022-06-30
GK,Grece,Pre-Market,CA,Study Budget,,2022-06-30
GK,Grece,Post-Market,CA,I. Cover letter which will include a list of contents,,2022-06-30
GK,Grece,Post-Market,CA,"II. General Part: The documentation to be included in the General Part of the filing file to the EOF is set out in Annex XV, Chapter II of Regulation (EU) 2017/745.",,2022-06-30
GK,Grece,Post-Market,CA,Application Form,,2022-06-30
GK,Grece,Post-Market,CA,Investigator Brochure (IB),,2022-06-30
GK,Grece,Post-Market,CA,Clinical Investigation Plan (CIP),,2022-06-30
GK,Grece,Post-Market,CA,Compliance statement letter,,2022-06-30
GK,Grece,Post-Market,CA,Insurance certificate,,2022-06-30
GK,Grece,Post-Market,CA,Patient informed consent form (ICF),,2022-06-30
GK,Grece,Post-Market,CA,Data confidentiality letter,,2022-06-30
GK,Grece,Post-Market,CA,Instruction for use (IFU),,2022-06-30
GK,Grece,Post-Market,CA,Case report form (CRF),,2022-06-30
GK,Grece,Post-Market,CA,"III. Special Part: In addition to the supporting documents of the General Part, the file to the EOF will include the following Special supporting documents:",,2022-06-30
GK,Grece,Post-Market,CA,"Completed the application form in Greek (available on the EOF website), in searchable pdf format, with signature, signatory details and date  ",,2022-06-30
GK,Grece,Post-Market,CA,"General Summary of the clinical investigation plan (SYNOPSIS) in the Greek language (Relative to Section 3.1.5 of Reg. 2017/745, Par. XV, Chapter II)",,2022-06-30
GK,Grece,Post-Market,CA,"Patient information and consent form (s), in Greek (& original in English if available). ",,2022-06-30
GK,Grece,Post-Market,CA,Agreement PI & Sponsor,,2022-06-30
GK,Grece,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
GK,Grece,Post-Market,CA,"If the applicant is not the sponsor, a letter of authorization to the applicant to act on behalf of the sponsor.",,2022-06-30
GK,Grece,Post-Market,CA,CE marking certificate (if aplicable),,2022-06-30
GK,Grece,Post-Market,CA,"Model of the label in the Greek language in which there will be, among other information, the labeling ""exclusively for clinical trials"".",,2022-06-30
GK,Grece,Post-Market,CA,"Responsible statement from the sponsor stating whether the product contains as an integral part of the substance or derivative of human blood (in addition to Point 2.6 of Reg. 2017/745, Par. XV, Chapter II).",,2022-06-30
GK,Grece,Post-Market,CA,Proof of payment of a fee in favor of EOF,,2022-06-30
GK,Grece,Post-Market,CA,Study Budget,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Cover Letter,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Proof of payment,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Ethical favorable opinion from EC,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,APLICATION FORM ,See MDCG 2021-08 guide,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,"A description compiled for the examiner, the content of which complies with the provisions of MDR XV.",,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,CIP,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Monitoring plan if not included in CIP,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Synopsis,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,IFU,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Documentation ofr comparator device,If aplicable,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Technical documention. Device information,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Proof of insurance,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,"Documents to be used to obtain the informed consent, including the package leaflet and the informed consent",Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Data protection,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Agreements between parties ,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,"PI CVs, GCPs",Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,A statement from the head of the medical institution providing the test site stating that he is aware of the intention to conduct the test agrees with the personal and material conditions are provided for the investigation.,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Cover Letter,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Proof of payment,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Ethical favorable opinion from EC,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,APLICATION FORM ,See MDCG 2021-08 guide,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,"A description compiled for the examiner, the content of which complies with the provisions of MDR XV.",,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,CIP,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Monitoring plan if not included in CIP,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Synopsis,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,CE Certificate ,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,IFU,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Documentation ofr comparator device,If aplicable,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Technical documention. Device information,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Proof of insurance,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,"Documents to be used to obtain the informed consent, including the package leaflet and the informed consent",Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Data protection,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Agreements between parties ,Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,"PI CVs, GCPs",Hungarian,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,A statement from the head of the medical institution providing the test site stating that he is aware of the intention to conduct the test agrees with the personal and material conditions are provided for the investigation.,Hungarian,2022-06-30
IE,Ireland,Pre-Market,CA,Application form,Download from web,2022-06-30
IE,Ireland,Pre-Market,CA,CIP,"Version and Date, and amendments",2022-06-30
IE,Ireland,Pre-Market,CA,Statement of compliance with the recognised ethical principles for medical research involving humans and the principles of good clinical practice in the field of clinical investigations of devices and with applicable regulatory requirements,,2022-06-30
IE,Ireland,Pre-Market,CA,Sponsor's contact details,,2022-06-30
IE,Ireland,Pre-Market,CA,"Identification of the principal investigator at each investigational site, the coordinating investigator, address details for each investigational site, emergency contact details for the principal investigator at each site. The roles, responsibilities and qualifications of the investigators must also be specified in the CIP.",,2022-06-30
IE,Ireland,Pre-Market,CA,Funding & agreements,,2022-06-30
IE,Ireland,Pre-Market,CA,Synopsis ,In EN,2022-06-30
IE,Ireland,Pre-Market,CA,Identification and description of the device,,2022-06-30
IE,Ireland,Pre-Market,CA,Risk assessments ,,2022-06-30
IE,Ireland,Pre-Market,CA,Description of the relevance of the clinical investigation in the context of the state of the art of clinical practice,,2022-06-30
IE,Ireland,Pre-Market,CA,Objectives and hypotheses of the clinical investigation,,2022-06-30
IE,Ireland,Pre-Market,CA,"Full description and justification of investigation design with evidence of its scientific robustness and validity, including criteria used for decision making, e.g. meeting end point, stopping criteria",,2022-06-30
IE,Ireland,Pre-Market,CA,ICF & patient information,,2022-06-30
IE,Ireland,Pre-Market,CA,Policy regarding follow-up and management of any deviations from investigation protocol,,2022-06-30
IE,Ireland,Pre-Market,CA,Device accountability,,2022-06-30
IE,Ireland,Pre-Market,CA,"Proposed clinical and procedural follow-up protocols for participants, both during and after the clinical investigation, if applicable",,2022-06-30
IE,Ireland,Pre-Market,CA,Data management plan,,2022-06-30
IE,Ireland,Pre-Market,CA,Monitoring plan,,2022-06-30
IE,Ireland,Pre-Market,CA,Safety reports,,2022-06-30
IE,Ireland,Pre-Market,CA,IB ,,2022-06-30
IE,Ireland,Pre-Market,CA,Pre-clinical & clinical information ,,2022-06-30
IE,Ireland,Pre-Market,CA,EC ,,2022-06-30
IE,Ireland,Pre-Market,CA,Copy of Opinion of the EC,,2022-06-30
IE,Ireland,Pre-Market,CA,Proof of insurance,,2022-06-30
IE,Ireland,Post-Market,CA,Aplication Form,Download from web,2022-06-30
IE,Ireland,Post-Market,CA,CIP,"Dated, Version No",2022-06-30
IE,Ireland,Post-Market,CA,IB OR IFU,,2022-06-30
IE,Ireland,Post-Market,CA,Opinion from EC,,2022-06-30
IE,Ireland,Post-Market,CA,Documents used to obtain informed consent,,2022-06-30
IE,Ireland,Post-Market,CA,Statement on Data Protection,,2022-06-30
IE,Ireland,Post-Market,CA,CE marking,,2022-06-30
IE,Ireland,Post-Market,CA,"PI Cvs, GCPs",,2022-06-30
IS,Iceland,Pre-Market,CA,MANDATORY,,2022-06-30
IS,Iceland,Pre-Market,CA,Cover letter,,2022-06-30
IS,Iceland,Pre-Market,CA,Application form,,2022-06-30
IS,Iceland,Pre-Market,CA,Investigator’s Brochure (including any annexes) ,,2022-06-30
IS,Iceland,Pre-Market,CA,CIP,,2022-06-30
IS,Iceland,Pre-Market,CA,CEP,,2022-06-30
IS,Iceland,Pre-Market,CA,Synopsis,,2022-06-30
IS,Iceland,Pre-Market,CA,Statement of conformity,,2022-06-30
IS,Iceland,Pre-Market,CA,Example of labels,,2022-06-30
IS,Iceland,Pre-Market,CA,The protection and confidentiality of personal data/ personal information,,2022-06-30
IS,Iceland,Pre-Market,CA,List of GSPRs,,2022-06-30
IS,Iceland,Pre-Market,CA,AS APLICABLE,,2022-06-30
IS,Iceland,Pre-Market,CA,Risk management documentation,,2022-06-30
IS,Iceland,Pre-Market,CA,Test reports,,2022-06-30
IS,Iceland,Pre-Market,CA,Proof of Clinical Investigation Insurance,,2022-06-30
IS,Iceland,Pre-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
IS,Iceland,Pre-Market,CA,Manufacturer’s Instructions for Use,,2022-06-30
IS,Iceland,Pre-Market,CA,Suitability of the investigators,,2022-06-30
IS,Iceland,Pre-Market,CA,Recruitment procedures and advertising materials,,2022-06-30
IS,Iceland,Pre-Market,CA,"ICF, participants information, compensation….",,2022-06-30
IS,Iceland,Pre-Market,CA,Decisions from other countries,,2022-06-30
IS,Iceland,Post-Market,CA,MANDATORY,,2022-06-30
IS,Iceland,Post-Market,CA,Cover letter,,2022-06-30
IS,Iceland,Post-Market,CA,Application form,,2022-06-30
IS,Iceland,Post-Market,CA,Investigator’s Brochure (including any annexes) ,,2022-06-30
IS,Iceland,Post-Market,CA,CIP,,2022-06-30
IS,Iceland,Post-Market,CA,CEP,,2022-06-30
IS,Iceland,Post-Market,CA,Synopsis,,2022-06-30
IS,Iceland,Post-Market,CA,Statement of conformity,,2022-06-30
IS,Iceland,Post-Market,CA,Example of labels,,2022-06-30
IS,Iceland,Post-Market,CA,The protection and confidentiality of personal data/ personal information,,2022-06-30
IS,Iceland,Post-Market,CA,List of GSPRs,,2022-06-30
IS,Iceland,Post-Market,CA,AS APLICABLE,,2022-06-30
IS,Iceland,Post-Market,CA,Risk management documentation,,2022-06-30
IS,Iceland,Post-Market,CA,Test reports,,2022-06-30
IS,Iceland,Post-Market,CA,Proof of Clinical Investigation Insurance,,2022-06-30
IS,Iceland,Post-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
IS,Iceland,Post-Market,CA,Manufacturer’s Instructions for Use,,2022-06-30
IS,Iceland,Post-Market,CA,Suitability of the investigators,,2022-06-30
IS,Iceland,Post-Market,CA,Recruitment procedures and advertising materials,,2022-06-30
IS,Iceland,Post-Market,CA,"ICF, participants information, compensation….",,2022-06-30
IS,Iceland,Post-Market,CA,CE Certificate,,2022-06-30
IS,Iceland,Post-Market,CA,Decisions from other countries,,2022-06-30
IS,Iceland,Post-Market,CA,PMCF Plan,,2022-06-30
IT,Italy,Pre-Market,CA,Letter of request, Italian or bilingual Italian/ English,2022-06-30
IT,Italy,Pre-Market,CA,Application form (IT or EN version),"Italian or English, including Appendix showing the list of documents supporting the application.",2022-06-30
IT,Italy,Pre-Market,CA,Investigator's dossier,"Manufacturer's Instructions, Label Examples, Instructions for Use, List of General Safety and Performance Requirements and Applicable Standards, Summary of Risk, Benefit and risk management",2022-06-30
IT,Italy,Pre-Market,CA,CIP with Synopsis ,Same language CIP & Synopsis,2022-06-30
IT,Italy,Pre-Market,CA,Declaration that devices complies with the GSPRs ,,2022-06-30
IT,Italy,Pre-Market,CA,Copy of the opinion / single opinion issued by the Ethics Committee / Coordinating Ethics Committee ,depending on whether the trial centers in Italy are one or more than one,2022-06-30
IT,Italy,Pre-Market,CA,Proof of insurance coverage or indemnification,,2022-06-30
IT,Italy,Pre-Market,CA,"ICF, including the patient information sheet ",Italian,2022-06-30
IT,Italy,Pre-Market,CA,Protection and confidentiality of personal data,,2022-06-30
IT,Italy,Pre-Market,CA,"Proof of payment of the fee of € 2,245.20",,2022-06-30
IT,Italy,Pre-Market,CA,Substitutive declaration of the deed of notoriety of the natural person acting as the legal representative of the Sponsor,Download from webpage ,2022-06-30
IT,Italy,Pre-Market,CA,Substitutive declaration of the deed of notoriety of the natural person acting as legal representative of the manufacturing manager,Download from webpage,2022-06-30
IT,Italy,Pre-Market,CA,Copy of any power of attorney to the person who submits the application and is the recipient of the communications from the Competent Authority,Download from webpage,2022-06-30
IT,Italy,Pre-Market,CA,Documentation relating to the suitability of the health facility (s) of the investigator (s),,2022-06-30
IT,Italy,Pre-Market,CA,"List of trial centers and related ethics committees, including all their PEC addresses",,2022-06-30
IT,Italy,Pre-Market,CA,"Other documents, where applicable ","e.g. Opinion of the group of experts, Decisions of other Competent Authorities, PMCF Plan, Documentation of recruitment procedures and advertising material, any opinions of other Ethics Committees)",2022-06-30
IT,Italy,Pre-Market,CA,Investigator's application dated and signed,,2022-06-30
IT,Italy,Pre-Market,CA,"If the study is sponsored, receipt of the transfer or declaration from the Promoter in the case of a non-profit study",,2022-06-30
IT,Italy,Pre-Market,CA,EC documents list,,2022-06-30
IT,Italy,Pre-Market,CA,"Please submit the following application in this way: Send a hard copy and an electronic copy (cd-rom) of the documents listed below to the Secretariat Office of the Ethics Committee, Pav. 3 - New Entrance Careggi (NIC) - Didactics - Largo Brambilla, 3 - 50134 Florence",Region Toscana: https://www.aou-careggi.toscana.it/internet/index.php?option=com_content&view=article&id=4385&Itemid=962&lang=it,2022-06-30
IT,Italy,Pre-Market,CA,Documents ,Note,2022-06-30
IT,Italy,Pre-Market,CA,Letter of Intent (Form in webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Synopsis in Italian (Form in webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Complete study protocol and any amendments with version and date on each page (CIP),,2022-06-30
IT,Italy,Pre-Market,CA,List of participating sites,,2022-06-30
IT,Italy,Pre-Market,CA,Data collection information (CRF),,2022-06-30
IT,Italy,Pre-Market,CA,Insurance certificate in Italian (if applicable),,2022-06-30
IT,Italy,Pre-Market,CA,Receipt of the payment of the amount established by the Tuscany Region for the examination of the study protocol,,2022-06-30
IT,Italy,Pre-Market,CA,Economic agreement (Form on webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Informed Consent Form in Italian (Form on webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Device user manual = IFU?,,2022-06-30
IT,Italy,Pre-Market,CA,CE Marking Certification ,,2022-06-30
IT,Italy,Pre-Market,CA,Device Preliminary CheckList (Form in webpage),CHECK if the device has registered in Italy. https://www.salute.gov.it/interrogazioneDispositivi/RicercaDispositiviServlet?action=ACTION_MASCHERA ,2022-06-30
IT,Italy,Pre-Market,CA,PI Acceptance Form (on webpage),,2022-06-30
IT,Italy,Pre-Market,CA,"PI CVs, GCPs.. Up to date",,2022-06-30
IT,Italy,Pre-Market,CA,Feasibility Assessment (Form on webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Public Statement on Local Investigator's Conflict of Interest (Form on webpage),,2022-06-30
IT,Italy,Post-Market,CA,Letter of request, Italian or bilingual Italian/ English,2022-06-30
IT,Italy,Post-Market,CA,Application form (download from web IT/EN version),"Italian or English, including Appendix showing the list of documents supporting the application.",2022-06-30
IT,Italy,Post-Market,CA,Investigator's dossier,"Manufacturer's Instructions, Label Examples, Instructions for Use, List of General Safety and Performance Requirements and Applicable Standards, Summary of Risk, Benefit and risk management",2022-06-30
IT,Italy,Post-Market,CA,CIP with Synopsis ,Same language CIP & Synopsis,2022-06-30
IT,Italy,Post-Market,CA,Declaration that devices complies with the GSPRs ,,2022-06-30
IT,Italy,Post-Market,CA,Copy of the opinion / single opinion issued by the Ethics Committee / Coordinating Ethics Committee ,depending on whether the trial centers in Italy are one or more than one,2022-06-30
IT,Italy,Post-Market,CA,Proof of insurance coverage or indemnification,,2022-06-30
IT,Italy,Post-Market,CA,"ICF, including the patient information sheet ",Italian,2022-06-30
IT,Italy,Post-Market,CA,Protection and confidentiality of personal data,,2022-06-30
IT,Italy,Post-Market,CA,"Proof of payment of the fee of € 2,245.20",,2022-06-30
IT,Italy,Post-Market,CA,Substitutive declaration of the deed of notoriety of the natural person acting as the legal representative of the Sponsor,,2022-06-30
IT,Italy,Post-Market,CA,Substitutive declaration of the deed of notoriety of the natural person acting as legal representative of the manufacturing manager,,2022-06-30
IT,Italy,Post-Market,CA,Copy of any power of attorney to the person who submits the application and is the recipient of the communications from the Competent Authority,,2022-06-30
IT,Italy,Post-Market,CA,Documentation relating to the suitability of the health facility (s) of the investigator (s),,2022-06-30
IT,Italy,Post-Market,CA,"List of trial centers and related ethics committees, including all their PEC addresses",,2022-06-30
IT,Italy,Post-Market,CA,"Other documents, where applicable ","e.g. Opinion of the group of experts, Decisions of other Competent Authorities, PMCF Plan, Documentation of recruitment procedures and advertising material, any opinions of other Ethics Committees)",2022-06-30
LT,Lithuania,Pre-Market,CA,Application Form,Download from web https://e-seimas.lrs.lt/portal/legalAct/lt/TAD/6abb8a40302911eb8c97e01ffe050e1c?jfwid=-vvhf0h3w,2022-06-30
LT,Lithuania,Pre-Market,CA,CEP,Dated version and signed,2022-06-30
LT,Lithuania,Pre-Market,CA,"Information on whether the medical device contains a medicinal substance, including a human blood or plasma derivative, or is manufactured using non-viable tissues or cells or derivatives thereof of human or animal origin",,2022-06-30
LT,Lithuania,Pre-Market,CA,Summary of the clinical trial design,"the purpose (s) of the clinical trial, the number and sex of subjects, the selection criteria, the design of the study in subjects under 18 years of age, such as controlled and / or randomized trials study, scheduled start and end dates of the clinical trial",2022-06-30
LT,Lithuania,Pre-Market,CA,"Infromation of the comparartor, if applicable",,2022-06-30
LT,Lithuania,Pre-Market,CA,Site sustainability ,,2022-06-30
LT,Lithuania,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
LT,Lithuania,Pre-Market,CA,Statement of the sporsor about compliance with GSPRs,,2022-06-30
LT,Lithuania,Pre-Market,CA,IB,,2022-06-30
LT,Lithuania,Pre-Market,CA,CIP,,2022-06-30
LT,Lithuania,Pre-Market,CA,Proof of insurance,,2022-06-30
LT,Lithuania,Pre-Market,CA,Patient information & ICF,,2022-06-30
LT,Lithuania,Pre-Market,CA,More information (see notes),The Committee receives all the documents directly from the Agency. There is no direct communication between the Committee and the applicant (sponsor) following the new procedures.,2022-06-30
LT,Lithuania,Post-Market,CA,Application Form,Download from web https://e-seimas.lrs.lt/portal/legalAct/lt/TAD/6abb8a40302911eb8c97e01ffe050e1c?jfwid=-vvhf0h3w,2022-06-30
LT,Lithuania,Post-Market,CA,CEP,Dated version and signed,2022-06-30
LT,Lithuania,Post-Market,CA,"Information on whether the medical device contains a medicinal substance, including a human blood or plasma derivative, or is manufactured using non-viable tissues or cells or derivatives thereof of human or animal origin",,2022-06-30
LT,Lithuania,Post-Market,CA,Summary of the clinical trial design,"the purpose (s) of the clinical trial, the number and sex of subjects, the selection criteria, the design of the study in subjects under 18 years of age, such as controlled and / or randomized trials study, scheduled start and end dates of the clinical trial",2022-06-30
LT,Lithuania,Post-Market,CA,"Infromation of the comparartor, if applicable",,2022-06-30
LT,Lithuania,Post-Market,CA,Site sustainability ,,2022-06-30
LT,Lithuania,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
LT,Lithuania,Post-Market,CA,Statement of the sporsor about compliance with GSPRs,,2022-06-30
LT,Lithuania,Post-Market,CA,IB,,2022-06-30
LT,Lithuania,Post-Market,CA,CIP,,2022-06-30
LT,Lithuania,Post-Market,CA,Proof of insurance,,2022-06-30
LT,Lithuania,Post-Market,CA,Patient information & ICF,,2022-06-30
LV,Latvia,Pre-Market,CA,Cover Letter,,2022-06-30
LV,Latvia,Pre-Market,CA,Aplication form ,Download from the web,2022-06-30
LV,Latvia,Pre-Market,CA,Protocols,,2022-06-30
LV,Latvia,Pre-Market,CA,Proof of insurnace,,2022-06-30
LV,Latvia,Pre-Market,CA,CE marking certification,,2022-06-30
LV,Latvia,Pre-Market,CA,Description of the initiated surveillance and control method of clinical trial,,2022-06-30
LV,Latvia,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
LV,Latvia,Pre-Market,CA,An example of a register form for data obtained through clinical trial ,version number and date,2022-06-30
LV,Latvia,Pre-Market,CA,Written statement of PI that the clinical trial will be performed according to the trial plan and in compliance with requirements set out in the regilatory enactments ,,2022-06-30
LV,Latvia,Pre-Market,CA,Patient information and ICF,,2022-06-30
LV,Latvia,Pre-Market,CA,Description of identification measures for the research involving person,,2022-06-30
LV,Latvia,Pre-Market,CA,Recruitment plan,,2022-06-30
LV,Latvia,Pre-Market,CA,"Operational parameters of a medical device, malfunctions of the device and control of the measures related to elimination of malfunctions",,2022-06-30
LV,Latvia,Pre-Market,CA,EC favorable opinion. If aplicable,,2022-06-30
LV,Latvia,Post-Market,CA,Cover Letter,,2022-06-30
LV,Latvia,Post-Market,CA,Aplication form ,Download from the web,2022-06-30
LV,Latvia,Post-Market,CA,Protocols,,2022-06-30
LV,Latvia,Post-Market,CA,Proof of insurnace,,2022-06-30
LV,Latvia,Post-Market,CA,CE marking certification,,2022-06-30
LV,Latvia,Post-Market,CA,Description of the initiated surveillance and control method of clinical trial,,2022-06-30
LV,Latvia,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
LV,Latvia,Post-Market,CA,An example of a register form for data obtained through clinical trial ,version number and date,2022-06-30
LV,Latvia,Post-Market,CA,Written statement of PI that the clinical trial will be performed according to the trial plan and in compliance with requirements set out in the regilatory enactments ,,2022-06-30
LV,Latvia,Post-Market,CA,Patient information and ICF,,2022-06-30
LV,Latvia,Post-Market,CA,Description of identification measures for the research involving person,,2022-06-30
LV,Latvia,Post-Market,CA,Recruitment plan,,2022-06-30
LV,Latvia,Post-Market,CA,"Operational parameters of a medical device, malfunctions of the device and control of the measures related to elimination of malfunctions",,2022-06-30
LV,Latvia,Post-Market,CA,EC favorable opinion. If aplicable,,2022-06-30
LU,Luxembourg,Pre-Market,CA,Cover Letter ( Requesting authorisation for the study),File name: Protocol number_courrierAEC_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Pre-Market,CA,Aplication form ,,2022-06-30
LU,Luxembourg,Pre-Market,CA,EU test number & Universal test number ,,2022-06-30
LU,Luxembourg,Pre-Market,CA,Protocol ,File name: Protocol number_protocol_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Pre-Market,CA,Protocol summary/ Synopsis,File name: Protocol number_summary_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Pre-Market,CA,IB,File name: Protocol number_BI_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Pre-Market,CA,Dossier of the investigational product,,2022-06-30
LU,Luxembourg,Pre-Market,CA,"CE Certificate, if aplicable",,2022-06-30
LU,Luxembourg,Pre-Market,CA,Manufacturing and import authorization,,2022-06-30
LU,Luxembourg,Pre-Market,CA,Labeling of investigational product,,2022-06-30
LU,Luxembourg,Pre-Market,CA,"Scientific advice and pediatric investigation plan (PIP), if applicable",,2022-06-30
LU,Luxembourg,Pre-Market,CA,Technical File,File name: Protocol number_DT_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Pre-Market,CA,"CRF, evaluation grids, questionnaire",,2022-06-30
LU,Luxembourg,Pre-Market,CA,"PI Cvs, GCPs",,2022-06-30
LU,Luxembourg,Pre-Market,CA,ICF & patient information,French & German ,2022-06-30
LU,Luxembourg,Pre-Market,CA,Proof of insurance or compensation,,2022-06-30
LU,Luxembourg,Pre-Market,CA,Justification of the adequacy of the infrastructures,,2022-06-30
LU,Luxembourg,Pre-Market,CA,Study funding,,2022-06-30
LU,Luxembourg,Pre-Market,CA,Proof of payment fee,,2022-06-30
LU,Luxembourg,Pre-Market,CA,NOTE,The Luxembourg Ministry of Health is the only point of submission of files. The Ministry of Health is responsible for sending the study files to the Health Department and the National Research Ethics Committee.,2022-06-30
LU,Luxembourg,Post-Market,CA,Cover Letter ( Requesting authorisation for the study),File name: Protocol number_courrierAEC_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Post-Market,CA,Aplication form ,,2022-06-30
LU,Luxembourg,Post-Market,CA,EU test number & Universal test number ,,2022-06-30
LU,Luxembourg,Post-Market,CA,Protocol ,File name: Protocol number_protocol_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Post-Market,CA,Protocol summary/ Synopsis,File name: Protocol number_summary_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Post-Market,CA,IB,File name: Protocol number_BI_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Post-Market,CA,Dossier of the investigational product,,2022-06-30
LU,Luxembourg,Post-Market,CA,"CE Certificate, if aplicable",,2022-06-30
LU,Luxembourg,Post-Market,CA,Manufacturing and import authorization,,2022-06-30
LU,Luxembourg,Post-Market,CA,Labeling of investigational product,,2022-06-30
LU,Luxembourg,Post-Market,CA,"Scientific advice and pediatric investigation plan (PIP), if applicable",,2022-06-30
LU,Luxembourg,Post-Market,CA,Technical File,File name: Protocol number_DT_date(ddmmyy)_version,2022-06-30
LU,Luxembourg,Post-Market,CA,"CRF, evaluation grids, questionnaire",,2022-06-30
LU,Luxembourg,Post-Market,CA,"PI Cvs, GCPs",,2022-06-30
LU,Luxembourg,Post-Market,CA,ICF & patient information,French & German ,2022-06-30
LU,Luxembourg,Post-Market,CA,Proof of insurance or compensation,,2022-06-30
LU,Luxembourg,Post-Market,CA,Justification of the adequacy of the infrastructures,,2022-06-30
LU,Luxembourg,Post-Market,CA,Study funding,,2022-06-30
LU,Luxembourg,Post-Market,CA,Proof of payment fee,,2022-06-30
LU,Luxembourg,Post-Market,CA,NOTE,The Luxembourg Ministry of Health is the only point of submission of files. The Ministry of Health is responsible for sending the study files to the Health Department and the National Research Ethics Committee.,2022-06-30
MD,Republic of Moldova,Pre-Market,CA,Aplication Form (Annex I),2 copies of Annex I available from page http://lex.justice.md/index.php?action=view&view=doc&lang=1&id=375209,2022-06-30
MD,Republic of Moldova,Pre-Market,CA,Annex II,2 copies of Annex II available from page http://lex.justice.md/index.php?action=view&view=doc&lang=1&id=375209,2022-06-30
MD,Republic of Moldova,Pre-Market,CA,the manufacturer's registration certificate or other officially registered document,,2022-06-30
MD,Republic of Moldova,Pre-Market,CA,Authenticated declaration of conformity with the signature of the manufacturer and the authorized representative.,,2022-06-30
MD,Republic of Moldova,Pre-Market,CA,medical device label (including state language).,,2022-06-30
MD,Republic of Moldova,Pre-Market,CA,IFU,,2022-06-30
MD,Republic of Moldova,Pre-Market,CA,the document by which the manufacturer give the authorization to the representative in Moldova. ,authenticated by the signature of the manufacturer and the authorized representative.,2022-06-30
MD,Republic of Moldova,Post-Market,CA,Notification form ,"Annex I. 2 copies, download from ",2022-06-30
MD,Republic of Moldova,Post-Market,CA,the EC declaration of conformity issued by the manufacturer for the manufactured medical device;,,2022-06-30
MD,Republic of Moldova,Post-Market,CA,"the CE certificate of conformity valid for the manufactured devices, as the case may be;",,2022-06-30
MD,Republic of Moldova,Post-Market,CA,the act by which the manufacturer appoints his representative.,Signatures of both in the documents,2022-06-30
MD,Republic of Moldova,Post-Market,CA,the declaration on his own responsibility regarding the veracity of the data presented .,Annex II,2022-06-30
MD,Republic of Moldova,Post-Market,CA,Note: , the file is submitted on paper at the entrance to the Agency in the mailbox. Check if the devices is registed in the state web: http://89.32.230.138:8081/dispozitive/ ,2022-06-30
NL,Netherlands,Pre-Market,CA,NOTE,See requirement for EC. Same,2022-06-30
NL,Netherlands,Post-Market,CA,NOTE,See requirement for EC. Same,2022-06-30
NO,Norway,Pre-Market,CA,COMPULSORY DOCUMENTS,From 1 to 15,2022-06-30
NO,Norway,Pre-Market,CA,Documentation requirements and overview of submitted documents (this document),Download from website,2022-06-30
NO,Norway,Pre-Market,CA,Cover Letter,Please use the template provided by NoMA,2022-06-30
NO,Norway,Pre-Market,CA,Aplication form,Please use the template provided by NoMA,2022-06-30
NO,Norway,Pre-Market,CA,Appendix I,Please use the template provided by NoMA,2022-06-30
NO,Norway,Pre-Market,CA,IB,Fullfill the requirments according to chapter 2 Annex XV 2.1 to 2.8 MDR,2022-06-30
NO,Norway,Pre-Market,CA,CIP,"CIP shall fulfill the requirements of MDR, Annex XV, chapter II, 3.1 - 3.19 and preferably follow its layout with regards to subtitles.",2022-06-30
NO,Norway,Pre-Market,CA,Synopsis,"In Norwegian & in English. Annex XV, chapter II, 3.1.5",2022-06-30
NO,Norway,Pre-Market,CA,Signed statement that the device conforms to regulatory requirements,"Annex XV, chapter II, 4.1 or use the templeate provided by NoMA",2022-06-30
NO,Norway,Pre-Market,CA,MDR Annex XV check list for CIP and IB,Please use the template provided by NoMA,2022-06-30
NO,Norway,Pre-Market,CA,GSPRs checklist,Please use the template provided by NoMA,2022-06-30
NO,Norway,Pre-Market,CA,Proof of insurance,A copy of the insurance policy or written confirmation from The Norwegian System of Patient Injury Compensation (NPE,2022-06-30
NO,Norway,Pre-Market,CA,Documents to be used to obtain informed consent. Including the patient information sheet and the informed consent document. ,Templates are found on the Regional Ethics Committees web site,2022-06-30
NO,Norway,Pre-Market,CA,Data protection Statement,,2022-06-30
NO,Norway,Pre-Market,CA,Site sustainability ,,2022-06-30
NO,Norway,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
NO,Norway,Pre-Market,CA,IF APLICABLE ,From 16 to 19,2022-06-30
NO,Norway,Pre-Market,CA,Appendix 2 of aplication Form,If more than one investigational device is involved in the clinical investigation,2022-06-30
NO,Norway,Pre-Market,CA,Appendix 3 of Aplication Form,If more than one comparator device is involved in the clinical investigation,2022-06-30
NO,Norway,Pre-Market,CA,Opinion from an Expert panel,according to MDR Article 62.2,2022-06-30
NO,Norway,Pre-Market,CA,"Documentation according to MDR, Annex XV, chapter II, 2.5","Shall be submitted if the investigational device: -  incorporates a medicinal substance, including a human blood or plasma derivative, or is manufactured utilising non-viable tissues or cells of human or animal origin, or their derivatives",2022-06-30
NO,Norway,Pre-Market,CA,NOTE,"The application is sent by e-mail to  medicininsk.utstyr@legemiddelverket.no . Mark the subject field with «Application for clinical trial of medical equipment», as well as the name of the sponsor and the equipment. On the same day, the application is sent to REK via the REK portal. Documents required by REK are stated on their website . Documents sent to both instances must be identical.",2022-06-30
NO,Norway,Post-Market,CA,COMPULSORY DOCUMENTS,From 1 to 15,2022-06-30
NO,Norway,Post-Market,CA,Documentation requirements and overview of submitted documents (this document),Download from website,2022-06-30
NO,Norway,Post-Market,CA,Cover Letter,Please use the template provided by NoMA,2022-06-30
NO,Norway,Post-Market,CA,Aplication form,Please use the template provided by NoMA,2022-06-30
NO,Norway,Post-Market,CA,Appendix I,Please use the template provided by NoMA,2022-06-30
NO,Norway,Post-Market,CA,IB,Fullfill the requirments according to chapter 2 Annex XV 2.1 to 2.8 MDR,2022-06-30
NO,Norway,Post-Market,CA,CIP,"CIP shall fulfill the requirements of MDR, Annex XV, chapter II, 3.1 - 3.19 and preferably follow its layout with regards to subtitles.",2022-06-30
NO,Norway,Post-Market,CA,Synopsis,"In Norwegian & in English. Annex XV, chapter II, 3.1.5",2022-06-30
NO,Norway,Post-Market,CA,Signed statement that the device conforms to regulatory requirements,"Annex XV, chapter II, 4.1 or use the templeate provided by NoMA",2022-06-30
NO,Norway,Post-Market,CA,MDR Annex XV check list for CIP and IB,Please use the template provided by NoMA,2022-06-30
NO,Norway,Post-Market,CA,GSPRs checklist,Please use the template provided by NoMA,2022-06-30
NO,Norway,Post-Market,CA,Proof of insurance,A copy of the insurance policy or written confirmation from The Norwegian System of Patient Injury Compensation (NPE,2022-06-30
NO,Norway,Post-Market,CA,Documents to be used to obtain informed consent. Including the patient information sheet and the informed consent document. ,Templates are found on the Regional Ethics Committees web site,2022-06-30
NO,Norway,Post-Market,CA,Data protection Statement,,2022-06-30
NO,Norway,Post-Market,CA,Site sustainability ,,2022-06-30
NO,Norway,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
NO,Norway,Post-Market,CA,IF APLICABLE ,From 16 to 19,2022-06-30
NO,Norway,Post-Market,CA,Appendix 2 of aplication Form,If more than one investigational device is involved in the clinical investigation,2022-06-30
NO,Norway,Post-Market,CA,Appendix 3 of Aplication Form,If more than one comparator device is involved in the clinical investigation,2022-06-30
NO,Norway,Post-Market,CA,Opinion from an Expert panel,according to MDR Article 62.2,2022-06-30
NO,Norway,Post-Market,CA,"Documentation according to MDR, Annex XV, chapter II, 2.5","Shall be submitted if the investigational device: -  incorporates a medicinal substance, including a human blood or plasma derivative, or is manufactured utilising non-viable tissues or cells of human or animal origin, or their derivatives",2022-06-30
NO,Norway,Post-Market,CA,Instruction,"The application is sent by e-mail to  medicininsk.utstyr@legemiddelverket.no . Mark the subject field with «Application for clinical trial of medical equipment», as well as the name of the sponsor and the equipment. On the same day, the application is sent to REK via the REK portal. Documents required by REK are stated on their website . Documents sent to both instances must be identical.",2022-06-30
NO,Norway,Post-Market,CA,Instruction 2,"The trial can start 30 days after the sponsor submitted the message, unless we inform you otherwise.",2022-06-30
PT,Portugal,Pre-Market,CA,Application for conducting a clinical study with the intervention of medical devices;,,2022-06-30
PT,Portugal,Pre-Market,CA,"The ""Notification form relating to medical devices intended for clinical investigations""",,2022-06-30
PT,Portugal,Pre-Market,CA,"The ""Declaration Template"" on devices - for pre-market studies involving medical devices.",,2022-06-30
PT,Portugal,Pre-Market,CA,Protocols (CIP),,2022-06-30
PT,Portugal,Pre-Market,CA,IB,,2022-06-30
PT,Portugal,Pre-Market,CA,ICF & Patient information,,2022-06-30
PT,Portugal,Pre-Market,CA,Proof of insurance,,2022-06-30
PT,Portugal,Pre-Market,CA,IFU and labelling,,2022-06-30
PT,Portugal,Pre-Market,CA,Opinion of the EC ,if available at time of submission,2022-06-30
PT,Portugal,Pre-Market,CA,"PI CVs, GCPs","updated, signed",2022-06-30
PT,Portugal,Pre-Market,CA,Proof of fee payment,,2022-06-30
PT,Portugal,Post-Market,CA,Application for conducting a clinical study with the intervention of medical devices;,Download: https://www.infarmed.pt/web/infarmed/entidades/dispositivos-medicos/investigacao-clinica-avaliacao-funcional/investigacao_clinica,2022-06-30
PT,Portugal,Post-Market,CA,"The ""Notification form relating to medical devices intended for clinical investigations""",https://www.infarmed.pt/web/infarmed/entidades/dispositivos-medicos/investigacao-clinica-avaliacao-funcional/investigacao_clinica,2022-06-30
PT,Portugal,Post-Market,CA,"The ""Declaration Template"" on devices - for pre-market studies involving medical devices.",https://www.infarmed.pt/web/infarmed/entidades/dispositivos-medicos/investigacao-clinica-avaliacao-funcional/investigacao_clinica,2022-06-30
PT,Portugal,Post-Market,CA,Protocols (CIP),,2022-06-30
PT,Portugal,Post-Market,CA,IB,,2022-06-30
PT,Portugal,Post-Market,CA,ICF & Patient information,,2022-06-30
PT,Portugal,Post-Market,CA,Proof of insurance,,2022-06-30
PT,Portugal,Post-Market,CA,IFU and labelling,,2022-06-30
PT,Portugal,Post-Market,CA,Opinion of the EC ,if available at time of submission,2022-06-30
PT,Portugal,Post-Market,CA,"PI CVs, GCPs","updated, signed",2022-06-30
PT,Portugal,Post-Market,CA,Proof of fee payment,,2022-06-30
PT,Portugal,Post-Market,CA,Copy of the EC Declaration of Conformity,,2022-06-30
PT,Portugal,Post-Market,CA,"Copy of the EC Certificate of Conformity, if applicable",,2022-06-30
PT,Portugal,Post-Market,CA,Instruction (See NOTE),"For performing clinical trials in Portugal, sponsors have to get authorization from the Competent Authority and ethical approval from the Ethics Committee (CEIC) plus approval from the National Data Protection Authority (CNPD – “Comissão Nacional de Proteção de Dados”).",2022-06-30
RO,Romania,Pre-Market,CA,"1.1. Name of manufacturer / authorized representative, address, telephone, contact details for communication",,2022-06-30
RO,Romania,Pre-Market,CA,1.2. If it is the first request for investigation / evaluation or resolution,,2022-06-30
RO,Romania,Pre-Market,CA,"1.3. If there is a recurrence related to the same device, the reference number (s) and previous data from the latest investigations",,2022-06-30
RO,Romania,Pre-Market,CA,1.4. Other Member States participating in the clinical investigation / performance evaluation as part of the multinational / multicentre study,,2022-06-30
RO,Romania,Pre-Market,CA,1.5. Signed declaration for GSPRs ,,2022-06-30
RO,Romania,Pre-Market,CA,"2.1. Device trade name; 2.2. Generic device name; 2.3. Device model name; 2.4. Model number, if any.",,2022-06-30
RO,Romania,Pre-Market,CA,"3.1. Classification
3.2. A complete description of the device",,2022-06-30
RO,Romania,Pre-Market,CA,3.5. Summary of experiences with any similar device.,,2022-06-30
RO,Romania,Pre-Market,CA,3.6 Benefits- risk analysis,,2022-06-30
RO,Romania,Pre-Market,CA,3.7. Summary and analysis of preclinical tests and experimental data,,2022-06-30
RO,Romania,Pre-Market,CA,3.17. Instructions for use IFU,,2022-06-30
RO,Romania,Pre-Market,CA,"4.1. Names, qualifications, professional position, addresses of clinical investigators, coordinating investigator, if any, from multi-center clinical investigation",,2022-06-30
RO,Romania,Pre-Market,CA,"4.2. PI CVs, GCPs",,2022-06-30
RO,Romania,Pre-Market,CA,4.3. Lists of sites,,2022-06-30
RO,Romania,Pre-Market,CA,4.4. Copy of the Ethics Committee's opinion,,2022-06-30
RO,Romania,Pre-Market,CA,4.5. Copy of the patient's informed consent,,2022-06-30
RO,Romania,Pre-Market,CA,4.6. Copy of the document on how to compensate the patient in case of deterioration of his health following the clinical investigation,,2022-06-30
RO,Romania,Pre-Market,CA,"4.7. The summary of the reference scientific literature that was the basis of the study, with analysis and bibliography, if applicable.",,2022-06-30
RO,Romania,Pre-Market,CA,CIP ,5.1 to 5.10 ,2022-06-30
RO,Romania,Pre-Market,CA,6.1. Description of the final results to demonstrate the performance and safety of the use of the device,,2022-06-30
RO,Romania,Pre-Market,CA,"6.2. Description of procedures and details of incident recording and reporting,",,2022-06-30
RO,Romania,Pre-Market,CA,"6.3. Description and justification of statistical data, analytical method and procedures.",,2022-06-30
RO,Romania,Post-Market,CA,"1.1. Name of manufacturer / authorized representative, address, telephone, contact details for communication",,2022-06-30
RO,Romania,Post-Market,CA,1.2. If it is the first request for investigation / evaluation or resolution,,2022-06-30
RO,Romania,Post-Market,CA,"1.3. If there is a recurrence related to the same device, the reference number (s) and previous data from the latest investigations",,2022-06-30
RO,Romania,Post-Market,CA,1.4. Other Member States participating in the clinical investigation / performance evaluation as part of the multinational / multicentre study,,2022-06-30
RO,Romania,Post-Market,CA,1.5. Signed declaration for GSPRs ,,2022-06-30
RO,Romania,Post-Market,CA,"2.1. Device trade name; 2.2. Generic device name; 2.3. Device model name; 2.4. Model number, if any.",,2022-06-30
RO,Romania,Post-Market,CA,"3.1. Classification
3.2. A complete description of the device",,2022-06-30
RO,Romania,Post-Market,CA,3.5. Summary of experiences with any similar device.,,2022-06-30
RO,Romania,Post-Market,CA,3.6 Benefits- risk analysis,,2022-06-30
RO,Romania,Post-Market,CA,3.7. Summary and analysis of preclinical tests and experimental data,,2022-06-30
RO,Romania,Post-Market,CA,3.17. Instructions for use IFU,,2022-06-30
RO,Romania,Post-Market,CA,"4.1. Names, qualifications, professional position, addresses of clinical investigators, coordinating investigator, if any, from multi-center clinical investigation",,2022-06-30
RO,Romania,Post-Market,CA,"4.2. PI CVs, GCPs",,2022-06-30
RO,Romania,Post-Market,CA,4.3. Lists of sites,,2022-06-30
RO,Romania,Post-Market,CA,4.4. Copy of the Ethics Committee's opinion,,2022-06-30
RO,Romania,Post-Market,CA,4.5. Copy of the patient's informed consent,,2022-06-30
RO,Romania,Post-Market,CA,4.6. Copy of the document on how to compensate the patient in case of deterioration of his health following the clinical investigation,,2022-06-30
RO,Romania,Post-Market,CA,"4.7. The summary of the reference scientific literature that was the basis of the study, with analysis and bibliography, if applicable.",,2022-06-30
RO,Romania,Post-Market,CA,CIP ,5.1 to 5.10 ,2022-06-30
RO,Romania,Post-Market,CA,6.1. Description of the final results to demonstrate the performance and safety of the use of the device,,2022-06-30
RO,Romania,Post-Market,CA,"6.2. Description of procedures and details of incident recording and reporting,",,2022-06-30
RO,Romania,Post-Market,CA,"6.3. Description and justification of statistical data, analytical method and procedures.",,2022-06-30
RS,Unknown,Pre-Market,CA,cover letter;,,2022-06-30
RS,Unknown,Pre-Market,CA,request for approval of conducting a clinical trial of a medical device;,,2022-06-30
RS,Unknown,Pre-Market,CA,"additional documentation, ie information required as a rule;",,2022-06-30
RS,Unknown,Pre-Market,CA,"reasons for categorization, ie classification in accordance with the Law;",,2022-06-30
RS,Unknown,Pre-Market,CA,statement and documentation in accordance with Annex 1 Annex VIII and Annex 3 Annex VI of the bylaw which regulates the basic requirements for medical devices;,,2022-06-30
RS,Unknown,Pre-Market,CA,other specific information (eg qualifications of the principal investigator and researchers).,,2022-06-30
RS,Unknown,Pre-Market,CA,Instruction for more information," Правилник о клиничким испитивањима медицинског средства “Сл. гласник РС”, бр. 91/2018 од 23.11.2018. This document can be downloaded from: https://www.alims.gov.rs/regulativa/medicinska-sredstva/pravilnici/",2022-06-30
RS,Unknown,Post-Market,CA,cover letter;,,2022-06-30
RS,Unknown,Post-Market,CA,request for approval of conducting a clinical trial of a medical device;,,2022-06-30
RS,Unknown,Post-Market,CA,"additional documentation, ie information required as a rule;",,2022-06-30
RS,Unknown,Post-Market,CA,"reasons for categorization, ie classification in accordance with the Law;",,2022-06-30
RS,Unknown,Post-Market,CA,statement and documentation in accordance with Annex 1 Annex VIII and Annex 3 Annex VI of the bylaw which regulates the basic requirements for medical devices;,,2022-06-30
RS,Unknown,Post-Market,CA,other specific information (eg qualifications of the principal investigator and researchers).,,2022-06-30
RS,Unknown,Post-Market,CA,Instruction for more information," Правилник о клиничким испитивањима медицинског средства “Сл. гласник РС”, бр. 91/2018 од 23.11.2018. This document can be downloaded from: https://www.alims.gov.rs/regulativa/medicinska-sredstva/pravilnici/",2022-06-30
SI,Slovenia,Pre-Market,CA,MANDATORY,,2022-06-30
SI,Slovenia,Pre-Market,CA,Cover letter,,2022-06-30
SI,Slovenia,Pre-Market,CA,Application form,,2022-06-30
SI,Slovenia,Pre-Market,CA,Investigator’s Brochure (including any annexes) ,,2022-06-30
SI,Slovenia,Pre-Market,CA,CIP,,2022-06-30
SI,Slovenia,Pre-Market,CA,CEP,,2022-06-30
SI,Slovenia,Pre-Market,CA,Synopsis,,2022-06-30
SI,Slovenia,Pre-Market,CA,Statement of conformity,,2022-06-30
SI,Slovenia,Pre-Market,CA,Example of labels,,2022-06-30
SI,Slovenia,Pre-Market,CA,The protection and confidentiality of personal data/ personal information,,2022-06-30
SI,Slovenia,Pre-Market,CA,List of GSPRs,,2022-06-30
SI,Slovenia,Pre-Market,CA,AS APLICABLE,,2022-06-30
SI,Slovenia,Pre-Market,CA,Risk management documentation,,2022-06-30
SI,Slovenia,Pre-Market,CA,Test reports,,2022-06-30
SI,Slovenia,Pre-Market,CA,Proof of Clinical Investigation Insurance,,2022-06-30
SI,Slovenia,Pre-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
SI,Slovenia,Pre-Market,CA,Manufacturer’s Instructions for Use,,2022-06-30
SI,Slovenia,Pre-Market,CA,Suitability of the investigators,,2022-06-30
SI,Slovenia,Pre-Market,CA,Recruitment procedures and advertising materials,,2022-06-30
SI,Slovenia,Pre-Market,CA,"ICF, participants information, compensation….",,2022-06-30
SI,Slovenia,Pre-Market,CA,Decisions from other countries,,2022-06-30
SI,Slovenia,Pre-Market,CA,Administration fee,https://www.uradni-list.si/glasilo-uradni-list-rs/vsebina/2019-01-1042/pravilnik-o-pristojbinah-na-podrocju-medicinskih-pripomockov,2022-06-30
SI,Slovenia,Pre-Market,CA,Check the registration of the device in Slovenia,the JAZMP’s Register of economic operators established in the Republic of Slovenia. Download form: https://www.jazmp.si/en/medical-devices/registration-of-medical-devices/registration-of-a-device-in-accordance-with-the-regulation-eu-2017-745-on-medical-devices/ ,2022-06-30
SI,Slovenia,Post-Market,CA,MANDATORY,,2022-06-30
SI,Slovenia,Post-Market,CA,Cover letter,,2022-06-30
SI,Slovenia,Post-Market,CA,Application form,,2022-06-30
SI,Slovenia,Post-Market,CA,Investigator’s Brochure (including any annexes) ,,2022-06-30
SI,Slovenia,Post-Market,CA,CIP,,2022-06-30
SI,Slovenia,Post-Market,CA,CEP,,2022-06-30
SI,Slovenia,Post-Market,CA,Synopsis,,2022-06-30
SI,Slovenia,Post-Market,CA,Statement of conformity,,2022-06-30
SI,Slovenia,Post-Market,CA,Example of labels,,2022-06-30
SI,Slovenia,Post-Market,CA,The protection and confidentiality of personal data/ personal information,,2022-06-30
SI,Slovenia,Post-Market,CA,List of GSPRs,,2022-06-30
SI,Slovenia,Post-Market,CA,AS APLICABLE,,2022-06-30
SI,Slovenia,Post-Market,CA,Risk management documentation,,2022-06-30
SI,Slovenia,Post-Market,CA,Test reports,,2022-06-30
SI,Slovenia,Post-Market,CA,Proof of Clinical Investigation Insurance,,2022-06-30
SI,Slovenia,Post-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
SI,Slovenia,Post-Market,CA,Manufacturer’s Instructions for Use,,2022-06-30
SI,Slovenia,Post-Market,CA,Suitability of the investigators,,2022-06-30
SI,Slovenia,Post-Market,CA,Recruitment procedures and advertising materials,,2022-06-30
SI,Slovenia,Post-Market,CA,"ICF, participants information, compensation….",,2022-06-30
SI,Slovenia,Post-Market,CA,Decisions from other countries,,2022-06-30
SI,Slovenia,Post-Market,CA,Administration fee,https://www.uradni-list.si/glasilo-uradni-list-rs/vsebina/2019-01-1042/pravilnik-o-pristojbinah-na-podrocju-medicinskih-pripomockov,2022-06-30
SI,Slovenia,Post-Market,CA,Check the registration of the device in Slovenia,the JAZMP’s Register of economic operators established in the Republic of Slovenia. Download form: https://www.jazmp.si/en/medical-devices/registration-of-medical-devices/registration-of-a-device-in-accordance-with-the-regulation-eu-2017-745-on-medical-devices/ ,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,MANDATORY,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Cover letter,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Application form,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Investigator’s Brochure (including any annexes) ,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,CIP,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,CEP,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Synopsis,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Statement of conformity,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Example of labels,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,The protection and confidentiality of personal data/ personal information,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,List of GSPRs,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Administration fee,"Administrative fee for the procedure for permitting a clinical trial of ZP in the amount of € 500
The administrative fee for issuing the Decision on the KS ZP permit is set at € 165.50",2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,AS APLICABLE,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Risk management documentation,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Test reports,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Proof of Clinical Investigation Insurance,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Manufacturer’s Instructions for Use,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Suitability of the investigators,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Recruitment procedures and advertising materials,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,"ICF, participants information, compensation….",,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Decisions from other countries,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,MANDATORY,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Cover letter,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Application form,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Investigator’s Brochure (including any annexes) ,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,CIP,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,CEP,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Synopsis,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Statement of conformity,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Example of labels,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,The protection and confidentiality of personal data/ personal information,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,List of GSPRs,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Administrative fee,Administrative fee for the procedure for permitting a clinical trial of ZP in the amount of € 500                The administrative fee for issuing the Decision on the KS ZP permit is set at € 165.50,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,AS APLICABLE,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Risk management documentation,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Test reports,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Proof of Clinical Investigation Insurance,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Suitability of investigational sites and investigation site team,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Manufacturer’s Instructions for Use,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Suitability of the investigators,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Recruitment procedures and advertising materials,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,"ICF, participants information, compensation….",,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,CE Certificate,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Decisions from other countries,,2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,PMCF Plan,,2022-06-30
SE,Sweden,Pre-Market,CA,1.1 Sponsor identification,,2022-06-30
SE,Sweden,Pre-Market,CA,1.2 Legal representative identification,Only if the sponsor is not from the EU,2022-06-30
SE,Sweden,Pre-Market,CA,1.3 investigation type (in online application),select the first alternative “Clinical investigation application,2022-06-30
SE,Sweden,Pre-Market,CA,1.4 Submission type,"First submission in the EEA” can be selected if this is the first submission of the investigation to a competent authority in any of the countries within the European Economic Area (EEA). Also, Select ”First submission at the national level” if it is the first submission of the investigation to
the Swedish MPA",2022-06-30
SE,Sweden,Pre-Market,CA,"1.5 Participating countries whin EU/EEA/UK, Northern Ireland, Turkey & Switzerland",,2022-06-30
SE,Sweden,Pre-Market,CA,1.6 Participating countries outside the above,,2022-06-30
SE,Sweden,Pre-Market,CA,1.7 CIP; 1.8 Title of the study,"Specify date, version, signature. Provide an unique CIP code",2022-06-30
SE,Sweden,Pre-Market,CA,2.1 Scientific opnion; 2.2 Design of the investigation; 2.3 Design methodology; 2.4 Development stage; 2.5 Objectives and endpoints,,2022-06-30
SE,Sweden,Pre-Market,CA,2.6 Synopsis ,,2022-06-30
SE,Sweden,Pre-Market,CA,Technical file about the device (3.1) ,,2022-06-30
SE,Sweden,Pre-Market,CA,3.2 Previous clinical investigation; 3.3 Scientific opinion/view; 3.4 Manufacturer of the investigational device ,,2022-06-30
SE,Sweden,Pre-Market,CA,4.1  & 4.2 Comparator device ,If aplicable,2022-06-30
SE,Sweden,Pre-Market,CA,"5.1 Site sustainability, list of centers, PI CVs and GCPs.",,2022-06-30
SE,Sweden,Pre-Market,CA,5.2 EC information,,2022-06-30
SE,Sweden,Pre-Market,CA,5.4 Expected number of subjects recruited within the Member State,,2022-06-30
SE,Sweden,Pre-Market,CA,Investigator Brochure IB,,2022-06-30
SE,Sweden,Post-Market,CA,1.1 Sponsor identification,,2022-06-30
SE,Sweden,Post-Market,CA,1.2 Legal representative identification,Only if the sponsor is not from the EU,2022-06-30
SE,Sweden,Post-Market,CA,1.3 investigation type (in online application),select “PMCF investigation notification”,2022-06-30
SE,Sweden,Post-Market,CA,1.4 Submission type,"First submission in the EEA” can be selected if this is the first submission of the investigation to a competent authority in any of the countries within the European Economic Area (EEA). Also, Select ”First submission at the national level” if it is the first submission of the investigation to
the Swedish MPA",2022-06-30
SE,Sweden,Post-Market,CA,"1.5 Participating countries whin EU/EEA/UK, Northern Ireland, Turkey & Switzerland",,2022-06-30
SE,Sweden,Post-Market,CA,1.6 Participating countries outside the above,,2022-06-30
SE,Sweden,Post-Market,CA,1.7 CIP; 1.8 Title of the study,"Specify date, version, signature. Provide an unique CIP code",2022-06-30
SE,Sweden,Post-Market,CA,2.1 Scientific opnion; 2.2 Design of the investigation; 2.3 Design methodology; 2.4 Development stage; 2.5 Objectives and endpoints,,2022-06-30
SE,Sweden,Post-Market,CA,2.6 Synopsis ,,2022-06-30
SE,Sweden,Post-Market,CA,Technical file about the device (3.1) ,,2022-06-30
SE,Sweden,Post-Market,CA,3.2 Previous clinical investigation; 3.3 Scientific opinion/view; 3.4 Manufacturer of the investigational device ,,2022-06-30
SE,Sweden,Post-Market,CA,4.1  & 4.2 Comparator device ,If aplicable,2022-06-30
SE,Sweden,Post-Market,CA,"5.1 Site sustainability, list of centers, PI CVs and GCPs.",,2022-06-30
SE,Sweden,Post-Market,CA,5.2 EC information,,2022-06-30
SE,Sweden,Post-Market,CA,5.4 Expected number of subjects recruited within the Member State,,2022-06-30
SE,Sweden,Post-Market,CA,Investigator brochure ,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Covering letter on headed paper,,2022-06-30
UK,United Kingdom,Pre-Market,CA,CIP,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Investigator’s brochure (IB),,2022-06-30
UK,United Kingdom,Pre-Market,CA,Participant information sheet,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Participant consent form (ICF),,2022-06-30
UK,United Kingdom,Pre-Market,CA,"PI CV, GCP",,2022-06-30
UK,United Kingdom,Pre-Market,CA,Device details,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Essential requirements checklist (GDPRs),,2022-06-30
UK,United Kingdom,Pre-Market,CA,Risk analysis,,2022-06-30
UK,United Kingdom,Pre-Market,CA,IFU,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Device labels,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Summary of all bench testing and pre-clinical testing conducted,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Summary of all clinical experience with the device to date,,2022-06-30
UK,United Kingdom,Pre-Market,CA,End of study reports for any concluded clinical investigations that involved the same medical device under investigation,,2022-06-30
UK,United Kingdom,Pre-Market,CA,List of standards met,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Sterilisation validation report (where relevant),,2022-06-30
UK,United Kingdom,Pre-Market,CA,Software information (where relevant),,2022-06-30
UK,United Kingdom,Pre-Market,CA,Biological safety assessments of patient contacting materials (where relevant),,2022-06-30
UK,United Kingdom,Pre-Market,CA,Information on animal tissues (where relevant),,2022-06-30
UK,United Kingdom,Pre-Market,CA,"Information on any medicine or human blood derivative, or non-viable human tissues and cells incorporated into the device",,2022-06-30
UK,United Kingdom,Pre-Market,CA,Research ethics committee opinion (if available),,2022-06-30
AT,Austria,Pre-Market,CA,Receipt of confirmation of EudraCT number,,2022-06-30
AT,Austria,Pre-Market,CA,Cover Letter ,,2022-06-30
AT,Austria,Pre-Market,CA,Application form,Signed and dated ,2022-06-30
AT,Austria,Pre-Market,CA,ICF,"local language, ",2022-06-30
AT,Austria,Pre-Market,CA,subject information leaflet,,2022-06-30
AT,Austria,Pre-Market,CA,Recruitment plan,,2022-06-30
AT,Austria,Pre-Market,CA,Protocols with all amendments ,,2022-06-30
AT,Austria,Pre-Market,CA,Synopsis in local language,,2022-06-30
AT,Austria,Pre-Market,CA,IB,,2022-06-30
AT,Austria,Pre-Market,CA,Summary of the products characteristic,,2022-06-30
AT,Austria,Pre-Market,CA,Centres list ,,2022-06-30
AT,Austria,Pre-Market,CA,"PI CVs, GCPs","updated, signed & dated",2022-06-30
AT,Austria,Pre-Market,CA,"All other staffs Cvs, GCPs","updated, signed & dated",2022-06-30
AT,Austria,Pre-Market,CA,Provision of indemnity or compensation,,2022-06-30
AT,Austria,Pre-Market,CA,Proof of Insurance,,2022-06-30
AT,Austria,Pre-Market,CA,Agreement between all parties,,2022-06-30
AT,Austria,Post-Market,CA,Receipt of confirmation of EudraCT number,,2022-06-30
AT,Austria,Post-Market,CA,Cover Letter ,,2022-06-30
AT,Austria,Post-Market,CA,Application form,Signed and dated ,2022-06-30
AT,Austria,Post-Market,CA,ICF,"local language, ",2022-06-30
AT,Austria,Post-Market,CA,subject information leaflet,,2022-06-30
AT,Austria,Post-Market,CA,Recruitment plan,,2022-06-30
AT,Austria,Post-Market,CA,Protocols with all amendments ,,2022-06-30
AT,Austria,Post-Market,CA,Synopsis in local language,,2022-06-30
AT,Austria,Post-Market,CA,IB,,2022-06-30
AT,Austria,Post-Market,CA,Summary of the products characteristic,,2022-06-30
AT,Austria,Post-Market,CA,Centres list ,,2022-06-30
AT,Austria,Post-Market,CA,"PI CVs, GCPs","updated, signed & dated",2022-06-30
AT,Austria,Post-Market,CA,"All other staffs Cvs, GCPs","updated, signed & dated",2022-06-30
AT,Austria,Post-Market,CA,Provision of indemnity or compensation,,2022-06-30
AT,Austria,Post-Market,CA,Proof of Insurance,,2022-06-30
AT,Austria,Post-Market,CA,Agreement between all parties,,2022-06-30
BY,Belarus,Pre-Market,CA,Register the device in the national system,Download form on webpgae. https://rceth.by/ru/Documents/Med/1 ,2022-06-30
BY,Belarus,Pre-Market,CA,Guide for researcher= IB,,2022-06-30
BY,Belarus,Pre-Market,CA,Protocol & amendments ,Dated and signed,2022-06-30
BY,Belarus,Pre-Market,CA,ICF in local language,,2022-06-30
BY,Belarus,Pre-Market,CA,Subjects recruiment,,2022-06-30
BY,Belarus,Pre-Market,CA,Documents on the financial aspect,,2022-06-30
BY,Belarus,Pre-Market,CA,Proof of Insurance,,2022-06-30
BY,Belarus,Pre-Market,CA,Agreement between the parties,,2022-06-30
BY,Belarus,Pre-Market,CA,Permission to conduct a clinical trial,,2022-06-30
BY,Belarus,Pre-Market,CA,"PI & other staffs Cvs, GCPs",,2022-06-30
BY,Belarus,Pre-Market,CA,IFU ,,2022-06-30
BY,Belarus,Pre-Market,CA,Invoices (postal receipts) for the supply of the investigated medical device and medical equipment,,2022-06-30
BY,Belarus,Post-Market,CA,Register the device in the national system,Download form on webpgae. https://rceth.by/ru/Documents/Med/1 ,2022-06-30
BY,Belarus,Post-Market,CA,Guide for researcher= IB,,2022-06-30
BY,Belarus,Post-Market,CA,Protocol & amendments ,Dated and signed,2022-06-30
BY,Belarus,Post-Market,CA,ICF in local language,,2022-06-30
BY,Belarus,Post-Market,CA,Subjects recruiment,,2022-06-30
BY,Belarus,Post-Market,CA,Documents on the financial aspect,,2022-06-30
BY,Belarus,Post-Market,CA,Proof of Insurance,,2022-06-30
BY,Belarus,Post-Market,CA,Agreement between the parties,,2022-06-30
BY,Belarus,Post-Market,CA,Permission to conduct a clinical trial,,2022-06-30
BY,Belarus,Post-Market,CA,"PI & other staffs Cvs, GCPs",,2022-06-30
BY,Belarus,Post-Market,CA,IFU ,,2022-06-30
BY,Belarus,Post-Market,CA,Invoices (postal receipts) for the supply of the investigated medical device and medical equipment,,2022-06-30
BE,Belgium,Pre-Market,CA,COVER LETTER,It should be clearly mentioned which Belgian regulatory pathway is applicable: Consolidated opinion FAMHP and EC ,2022-06-30
BE,Belgium,Pre-Market,CA,List of documents submitted ,Template on website,2022-06-30
BE,Belgium,Pre-Market,CA,APPLICATION FORM,Template on website,2022-06-30
BE,Belgium,Pre-Market,CA,"CIP (with Annexes, version and date)",,2022-06-30
BE,Belgium,Pre-Market,CA,Synopsis,,2022-06-30
BE,Belgium,Pre-Market,CA,INVESTIGATOR’S BROCHURE (With annexes),,2022-06-30
BE,Belgium,Pre-Market,CA,Example of labels,,2022-06-30
BE,Belgium,Pre-Market,CA,LIST OF GENERAL SAFETY AND PERFORMANCE REQUIREMENTS,Template on website,2022-06-30
BE,Belgium,Pre-Market,CA,MANUFACTURER’S IFU,,2022-06-30
BE,Belgium,Pre-Market,CA,CLINICAL EVALUATION PLAN,,2022-06-30
BE,Belgium,Pre-Market,CA,PROOF OF INSURANCE,,2022-06-30
BE,Belgium,Pre-Market,CA,"PI Cvs, GCPs, & DOI ",,2022-06-30
BE,Belgium,Pre-Market,CA,SUITABILITY OF SITE(S),,2022-06-30
BE,Belgium,Pre-Market,CA,Agreements between parties,,2022-06-30
BE,Belgium,Pre-Market,CA,RECRUITMENT AND ADVERTISING,,2022-06-30
BE,Belgium,Pre-Market,CA,"PATIENT INFO, ICF AND ICF PROCEDURE",,2022-06-30
BE,Belgium,Pre-Market,CA,FINANCIAL AND OTHER ARRANGEMENTS,,2022-06-30
BE,Belgium,Pre-Market,CA,STATEMENT ON DATA PROTECTION,,2022-06-30
BE,Belgium,Pre-Market,CA,"If multinational, status on submission procedure(s) in other countries, including any approval or refusal letter if applicable.",,2022-06-30
BE,Belgium,Pre-Market,CA,CE certificate and manufacturer’s instructions for use of any comparator device used,,2022-06-30
BE,Belgium,Post-Market,CA,COVER LETTER (Accusé de réception = AOR ),It should be clearly mentioned which Belgian regulatory pathway is applicable: EC ONLY,2022-06-30
BE,Belgium,Post-Market,CA,Avis du Comité d’Ethique ,,2022-06-30
BE,Belgium,Post-Market,CA,Questionnaire type ,,2022-06-30
BE,Belgium,Post-Market,CA,Letter of advice from the Central Committee.,,2022-06-30
BE,Belgium,Post-Market,CA,Synopsis,In French. Max 3 pages,2022-06-30
BE,Belgium,Post-Market,CA,Informed Consent Form ICF,In French compulsory. Other languages such as English & Dutch also available.,2022-06-30
BE,Belgium,Post-Market,CA,PROOF OF INSURANCE,The certificate must specify the expiry date of the insurance.,2022-06-30
BE,Belgium,Post-Market,CA,Receipt of payment,,2022-06-30
BE,Belgium,Post-Market,CA,RECRUITMENT AND ADVERTISING,,2022-06-30
BE,Belgium,Post-Market,CA,CIP with amendments,Signed & dated by the investigator,2022-06-30
BE,Belgium,Post-Market,CA,Contact details for the Central Ethics Committee and sites participating in the study,"Contact persons: e-mail addresses, addresses and telephone numbers.",2022-06-30
BE,Belgium,Post-Market,CA,"INVESTIGATOR(S) CV, GCPs",,2022-06-30
BE,Belgium,Post-Market,CA,Declaration of conflict of interest,dated and signed by all local investigators,2022-06-30
BE,Belgium,Post-Market,CA,FINANCIAL Agreements between the parties,,2022-06-30
BE,Belgium,Post-Market,CA,IB ,,2022-06-30
BE,Belgium,Post-Market,CA,CE Certificates,,2022-06-30
BE,Belgium,Post-Market,CA,Instruction for sending documents,"(digital version and paper version), with all the required documents (specified versions and dates).
Some documents are to be provided in digital version; others are to be provided in digital version AND in paper version (6 copies).
Digital documents must be sent:
• Either by e-mail: comite.ethique@ghdc.be
• Or by e-mail via a eudralink link
• Either on cd-rom, by post, to the following address: GHdC – Site Saint Joseph
Comité d’Ethique
Rue Marguerite Depasse 6
6060 GILLY ",2022-06-30
BG,Bulgaria,Pre-Market,CA,Cover Letter,,2022-06-30
BG,Bulgaria,Pre-Market,CA,Application Form (download from web),,2022-06-30
BG,Bulgaria,Pre-Market,CA,Administrative information (Download form) ,"Art. 2 of Regulation No10, 2008, of Ministry of Health",2022-06-30
BG,Bulgaria,Pre-Market,CA,Participant information,Art 3 ,2022-06-30
BG,Bulgaria,Pre-Market,CA,CIP,Art 4,2022-06-30
BG,Bulgaria,Pre-Market,CA,Device information,Art 5,2022-06-30
BG,Bulgaria,Pre-Market,CA,Documentation about medical institution technical resources and profecional qualification of investigating team,,2022-06-30
BG,Bulgaria,Pre-Market,CA,"PI CV, GCP",Art 6,2022-06-30
BG,Bulgaria,Pre-Market,CA,Financial source and administrative management ,Art 7,2022-06-30
BG,Bulgaria,Post-Market,CA,Cover Letter,,2022-06-30
BG,Bulgaria,Post-Market,CA,Application Form (download from web),,2022-06-30
BG,Bulgaria,Post-Market,CA,Administrative information (Download form) ,"Art. 2 of Regulation No10, 2008, of Ministry of Health",2022-06-30
BG,Bulgaria,Post-Market,CA,Participant information,Art 3 ,2022-06-30
BG,Bulgaria,Post-Market,CA,CIP,Art 4,2022-06-30
BG,Bulgaria,Post-Market,CA,Device information,Art 5,2022-06-30
BG,Bulgaria,Post-Market,CA,Documentation about medical institution technical resources and profecional qualification of investigating team,,2022-06-30
BG,Bulgaria,Post-Market,CA,"PI CV, GCP",Art 6,2022-06-30
BG,Bulgaria,Post-Market,CA,Financial source and administrative management ,Art 7,2022-06-30
CH,Switzerland,Pre-Market,CA,Cover Letter ,,2022-06-30
CH,Switzerland,Pre-Market,CA,Synopsis,Muticentric: Language of Lead EC or in English. Monocentric: Languge of EC. Template available,2022-06-30
CH,Switzerland,Pre-Market,CA,Participants information & ICF,Template available,2022-06-30
CH,Switzerland,Pre-Market,CA,Protocols,Signed & dated,2022-06-30
CH,Switzerland,Pre-Market,CA,Monitoring plan (if available),,2022-06-30
CH,Switzerland,Pre-Market,CA,CRF,Draft accepted. Final document within the next 30 days. ,2022-06-30
CH,Switzerland,Pre-Market,CA,"PI Cvs, GCPs",,2022-06-30
CH,Switzerland,Pre-Market,CA,Site sustainability,,2022-06-30
CH,Switzerland,Pre-Market,CA,Agreements between the parties,Template available,2022-06-30
CH,Switzerland,Pre-Market,CA,"Recruitment plan , questionnaires…",,2022-06-30
CH,Switzerland,Pre-Market,CA,Details on compensations,,2022-06-30
CH,Switzerland,Pre-Market,CA,Other personnels,Template available online,2022-06-30
CH,Switzerland,Pre-Market,CA,Information on handling personal Data,,2022-06-30
CH,Switzerland,Pre-Market,CA,"Information on reviews of this proposal by other Ethics Committees, or Regulatory Authorities (Foreign or Swiss)",If aplicable,2022-06-30
CH,Switzerland,Pre-Market,CA,"Sponsor Delegation Letter, signed",,2022-06-30
CH,Switzerland,Pre-Market,CA,Extra for each local EC:  Evidence/Statement from the sponsor on the ability to conduct the clinical investigation ,,2022-06-30
CH,Switzerland,Post-Market,CA,Cover Letter ,,2022-06-30
CH,Switzerland,Post-Market,CA,Synopsis,Muticentric: Language of Lead EC or in English. Monocentric: Languge of EC. Template available,2022-06-30
CH,Switzerland,Post-Market,CA,Participants information & ICF,Template available,2022-06-30
CH,Switzerland,Post-Market,CA,Protocols,Signed & dated,2022-06-30
CH,Switzerland,Post-Market,CA,Monitoring plan (if available),,2022-06-30
CH,Switzerland,Post-Market,CA,CRF,Draft accepted. Final document within the next 30 days. ,2022-06-30
CH,Switzerland,Post-Market,CA,"PI Cvs, GCPs",,2022-06-30
CH,Switzerland,Post-Market,CA,Site sustainability,,2022-06-30
CH,Switzerland,Post-Market,CA,Agreements between the parties,Template available,2022-06-30
CH,Switzerland,Post-Market,CA,"Recruitment plan , questionnaires…",,2022-06-30
CH,Switzerland,Post-Market,CA,Details on compensations,,2022-06-30
CH,Switzerland,Post-Market,CA,Other personnels,Template available online,2022-06-30
CH,Switzerland,Post-Market,CA,Information on handling personal Data,,2022-06-30
CH,Switzerland,Post-Market,CA,"Information on reviews of this proposal by other Ethics Committees, or Regulatory Authorities (Foreign or Swiss)",If aplicable,2022-06-30
CH,Switzerland,Post-Market,CA,"Sponsor Delegation Letter, signed",,2022-06-30
CH,Switzerland,Post-Market,CA,Extra for each local EC:  Evidence/Statement from the sponsor on the ability to conduct the clinical investigation ,,2022-06-30
CR,Costa Rica,Pre-Market,CA,Register as a user of the SEP Online database,,2022-06-30
CR,Costa Rica,Pre-Market,CA,Cover Letter,,2022-06-30
CR,Costa Rica,Pre-Market,CA,Protocol Summary Form (Test plan),,2022-06-30
CR,Costa Rica,Pre-Market,CA,Signed signature page of the valid version of the test plan by the new examiner,,2022-06-30
CR,Costa Rica,Pre-Market,CA,Confirmation of the payment ,,2022-06-30
CR,Costa Rica,Pre-Market,CA,"PI and Monitor Cvs, GCP (download form)","In Crotian, following the form. Signed and dated, updated no older than 6 months. Lead PI should have done at least 3 clinical trials, one of those has phase III. Download from: https://www.halmed.hr/en/O-HALMED-u/Sredisnje-eticko-povjerenstvo-SEP/Naputci-podnositeljima-zahtjeva/ ",2022-06-30
CR,Costa Rica,Pre-Market,CA,Financial plan/ signed contract with the distribution of funds between the institution and the examiner,"he amount of compensation to a legal entity and the examination team for visits is distributed in the ratio of 40% to the legal entity and 60% to the investigative team. team in case the institution has an established organizational unit for clinical trials, otherwise, the amount of compensation is distributed in the ratio of 20% to the legal entity and 80% to the research team",2022-06-30
CR,Costa Rica,Pre-Market,CA,Proof of insurance,In Croatian. ,2022-06-30
CR,Costa Rica,Pre-Market,CA,ICF ,,2022-06-30
CR,Costa Rica,Pre-Market,CA,Instruction for submission ,"Fill in the form and send it, signed and stamped by the responsible person of the applicant to IT Unit or to CEC per post to: Agency for Medicinal Products and Medical Devices of Croatia, Ksaverska cesta 4, 10 000 Zagreb, Republic of Croatia or personally to HALMED's Registry Office.",2022-06-30
CR,Costa Rica,Post-Market,CA,Register as a user of the SEP Online database,,2022-06-30
CR,Costa Rica,Post-Market,CA,Cover Letter,,2022-06-30
CR,Costa Rica,Post-Market,CA,Protocol Summary Form (Test plan),,2022-06-30
CR,Costa Rica,Post-Market,CA,Signed signature page of the valid version of the test plan by the new examiner,,2022-06-30
CR,Costa Rica,Post-Market,CA,Confirmation of the payment ,,2022-06-30
CR,Costa Rica,Post-Market,CA,"PI and Monitor Cvs, GCP (download form)","In Crotian, following the form. Signed and dated, updated no older than 6 months. Lead PI should have done at least 3 clinical trials, one of those has phase III. Download from:  https://www.halmed.hr/en/O-HALMED-u/Sredisnje-eticko-povjerenstvo-SEP/Naputci-podnositeljima-zahtjeva/ ",2022-06-30
CR,Costa Rica,Post-Market,CA,Financial plan/ signed contract with the distribution of funds between the institution and the examiner,"he amount of compensation to a legal entity and the examination team for visits is distributed in the ratio of 40% to the legal entity and 60% to the investigative team. team in case the institution has an established organizational unit for clinical trials, otherwise, the amount of compensation is distributed in the ratio of 20% to the legal entity and 80% to the research team",2022-06-30
CR,Costa Rica,Post-Market,CA,Proof of insurance,In Croatian. ,2022-06-30
CR,Costa Rica,Post-Market,CA,ICF ,,2022-06-30
CR,Costa Rica,Post-Market,CA,Instruction for submission ,"Fill in the form and send it, signed and stamped by the responsible person of the applicant to IT Unit or to CEC per post to: Agency for Medicinal Products and Medical Devices of Croatia, Ksaverska cesta 4, 10 000 Zagreb, Republic of Croatia or personally to HALMED's Registry Office.",2022-06-30
CY,Cyprus,Pre-Market,CA,Cover Letter,,2022-06-30
CY,Cyprus,Pre-Market,CA,EEBK02 (Application for Program Approval) download,Page 11 to 13 not for MDs,2022-06-30
CY,Cyprus,Pre-Market,CA,EEBK03 (Consent Form)/ Assent Form if aplicable,,2022-06-30
CY,Cyprus,Pre-Market,CA,The Research Proposal (CIP),,2022-06-30
CY,Cyprus,Pre-Market,CA,The Project budgets,,2022-06-30
CY,Cyprus,Pre-Market,CA,The Insurance Contract (where applicable),,2022-06-30
CY,Cyprus,Pre-Market,CA,The sponsor approval agreement ,,2022-06-30
CY,Cyprus,Pre-Market,CA,Proof of payment of the relevant bioethics fee evaluation.,,2022-06-30
CY,Cyprus,Pre-Market,CA,"PI CVs (max 2 pages), GCPs",,2022-06-30
CY,Cyprus,Pre-Market,CA,"Recruitment information (advertisements, flyers…)",,2022-06-30
CY,Cyprus,Pre-Market,CA,Instruction for submission ,NOTE: EBs will handle applications submitted at least 3 weeks prior to the date of their regular meetings.,2022-06-30
CY,Cyprus,Post-Market,CA,Cover Letter,,2022-06-30
CY,Cyprus,Post-Market,CA,EEBK02 (Application for Program Approval) download,Page 11 to 13 not for MDs,2022-06-30
CY,Cyprus,Post-Market,CA,EEBK03 (Consent Form)/ Assent Form if aplicable,,2022-06-30
CY,Cyprus,Post-Market,CA,The Research Proposal (CIP),,2022-06-30
CY,Cyprus,Post-Market,CA,The Project budgets,,2022-06-30
CY,Cyprus,Post-Market,CA,The Insurance Contract (where applicable),,2022-06-30
CY,Cyprus,Post-Market,CA,The sponsor approval agreement ,,2022-06-30
CY,Cyprus,Post-Market,CA,Proof of payment of the relevant bioethics fee evaluation.,,2022-06-30
CY,Cyprus,Post-Market,CA,"PI CVs (max 2 pages), GCPs",,2022-06-30
CY,Cyprus,Post-Market,CA,"Recruitment information (advertisements, flyers…)",,2022-06-30
CY,Cyprus,Post-Market,CA,Instruction for submission ,NOTE: EBs will handle applications submitted at least 3 weeks prior to the date of their regular meetings.,2022-06-30
CZ,Czech Republic,Pre-Market,CA,written contract between the sponsor of the clinical investigation and the provider of healthcare services,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,a written contract between the sponsor of the clinical investigation and the investigator,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Investigator's Brochure,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,CIP,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,ICF,Section 18 Act on MDs,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Insurance Cerificate,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,A declaration as to whether the medical device contains an active substance or a human blood or plasma derivative as its integral part,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,"declaration as to whether the medical device, with a view to minimising the risks of TSE infection transfer to humans, has been manufactured using tissues of animal origin (if aplicable)",,2022-06-30
CZ,Czech Republic,Pre-Market,CA,declaration that the concerned medical device meets basic requirements set forth for medical devices in conformity assessment (CE Certificate),,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Device information ,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,"PI CVs, GCP",,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Clinical Trial Agreement (CTA),,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Economic compensation (if Applicable),,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Payment detail ,,2022-06-30
CZ,Czech Republic,Pre-Market,CA,Sponsor Letter ,,2022-06-30
CZ,Czech Republic,Post-Market,CA,written contract between the sponsor of the clinical investigation and the provider of healthcare services,,2022-06-30
CZ,Czech Republic,Post-Market,CA,a written contract between the sponsor of the clinical investigation and the investigator,,2022-06-30
CZ,Czech Republic,Post-Market,CA,Investigator's Brochure,,2022-06-30
CZ,Czech Republic,Post-Market,CA,CIP,,2022-06-30
CZ,Czech Republic,Post-Market,CA,ICF,Section 18 Act on MDs,2022-06-30
CZ,Czech Republic,Post-Market,CA,Insurance Cerificate,,2022-06-30
CZ,Czech Republic,Post-Market,CA,A declaration as to whether the medical device contains an active substance or a human blood or plasma derivative as its integral part,,2022-06-30
CZ,Czech Republic,Post-Market,CA,"declaration as to whether the medical device, with a view to minimising the risks of TSE infection transfer to humans, has been manufactured using tissues of animal origin (if aplicable)",,2022-06-30
CZ,Czech Republic,Post-Market,CA,declaration that the concerned medical device meets basic requirements set forth for medical devices in conformity assessment (CE Certificate),,2022-06-30
CZ,Czech Republic,Post-Market,CA,Device information ,,2022-06-30
CZ,Czech Republic,Post-Market,CA,"PI CVs, GCP",,2022-06-30
CZ,Czech Republic,Post-Market,CA,Clinical Trial Agreement (CTA),,2022-06-30
CZ,Czech Republic,Post-Market,CA,Economic compensation (if Applicable),,2022-06-30
CZ,Czech Republic,Post-Market,CA,Payment detail ,,2022-06-30
CZ,Czech Republic,Post-Market,CA,Sponsor Letter ,,2022-06-30
DK,Denmark,Pre-Market,CA,Notification Form,Signed by PI and Sponsor,2022-06-30
DK,Denmark,Pre-Market,CA,Protocol,in DK or EN. Dated and signed,2022-06-30
DK,Denmark,Pre-Market,CA,Synopsis,in DK. Language for mon-medical experts,2022-06-30
DK,Denmark,Pre-Market,CA,Participant information,,2022-06-30
DK,Denmark,Pre-Market,CA,ICF,,2022-06-30
DK,Denmark,Pre-Market,CA,Questionnaires,,2022-06-30
DK,Denmark,Pre-Market,CA,Recruitment materials,,2022-06-30
DK,Denmark,Pre-Market,CA,Documentation of insurance cover ,IN DK,2022-06-30
DK,Denmark,Pre-Market,CA,Sponsor contracts,,2022-06-30
DK,Denmark,Pre-Market,CA,"PI CS, GCPS, ID information",,2022-06-30
DK,Denmark,Pre-Market,CA,"Sponsor company name, VAT no., ",If Sponsor submit the application ,2022-06-30
DK,Denmark,Post-Market,CA,Notification Form,Signed by PI and Sponsor,2022-06-30
DK,Denmark,Post-Market,CA,Protocol,in DK or EN. Dated and signed,2022-06-30
DK,Denmark,Post-Market,CA,Synopsis,in DK. Language for mon-medical experts,2022-06-30
DK,Denmark,Post-Market,CA,Participant information,,2022-06-30
DK,Denmark,Post-Market,CA,ICF,,2022-06-30
DK,Denmark,Post-Market,CA,Questionnaires,,2022-06-30
DK,Denmark,Post-Market,CA,Recruitment materials,,2022-06-30
DK,Denmark,Post-Market,CA,Documentation of insurance cover ,IN DK,2022-06-30
DK,Denmark,Post-Market,CA,Sponsor contracts,,2022-06-30
DK,Denmark,Post-Market,CA,"PI CS, GCPS, ID information",,2022-06-30
DK,Denmark,Post-Market,CA,"Sponsor company name, VAT no., ",If Sponsor submit the application ,2022-06-30
DE,Germany,Pre-Market,CA,CIP ,According to MDR Annex XV Chapter II. 3,2022-06-30
DE,Germany,Pre-Market,CA,IB,According to MDR Annex XV Chapter II. 2,2022-06-30
DE,Germany,Pre-Market,CA,Synopsis,in DE. According to MDR Annex XV Chapter II. 1.11,2022-06-30
DE,Germany,Pre-Market,CA,Description of the procedure,"A detailed description of the clinical procedures and diagnostic tests used during the course of the clinical investigation and, in particular, details of any deviations from usual practice",2022-06-30
DE,Germany,Pre-Market,CA,The pre-clinical evaluation,According to MDR Annex XV Chapter II. 2.3,2022-06-30
DE,Germany,Pre-Market,CA,IFU,Gebrauchsanweisung. According to MDR Annex XV Chapter II. 2.2,2022-06-30
DE,Germany,Pre-Market,CA,Risk analysis,According to MDR Annex XV Chapter II. 2.5,2022-06-30
DE,Germany,Pre-Market,CA,Signed statement for GSPRs,According to MDR Annex XV Chapter II. 4.1,2022-06-30
DE,Germany,Pre-Market,CA,Follow-up plan,According to MDR Annex XV Chapter II. 3.16 ,2022-06-30
DE,Germany,Pre-Market,CA,Power of Attorney for Representatives/ Vollmacht,According to MDR Annex XV Chapter II. 3.12,2022-06-30
DE,Germany,Pre-Market,CA,Site sustainability,According to MDR Annex XV Chapter II. 1.13,2022-06-30
DE,Germany,Pre-Market,CA,"PI Cvs, GCPs",,2022-06-30
DE,Germany,Pre-Market,CA,"Other staffs Cvs, GCPs",,2022-06-30
DE,Germany,Pre-Market,CA,Patient information & ICF,According to MDR Annex XV Chapter II. 4.4,2022-06-30
DE,Germany,Pre-Market,CA,Justification Inclusion of particularly vulnerable groups,If aplicable ,2022-06-30
DE,Germany,Pre-Market,CA,Proof of insurance,According to MDR Annex XV Chapter II. 4.5,2022-06-30
DE,Germany,Pre-Market,CA,Subjects compensation,According to MDR Annex XV Chapter II. 3.1.4,2022-06-30
DE,Germany,Pre-Market,CA,Data protection,,2022-06-30
DE,Germany,Pre-Market,CA,CTA,,2022-06-30
DE,Germany,Pre-Market,CA,Criteria and procedures for follow-up of subjects following the end of study,,2022-06-30
DE,Germany,Pre-Market,CA,CEP,According to MDR Annex XV Chapter II. 3.18,2022-06-30
DE,Germany,Pre-Market,CA,List  of technical documentation ,,2022-06-30
DE,Germany,Post-Market,CA,CIP ,According to MDR Annex XV Chapter II. 3,2022-06-30
DE,Germany,Post-Market,CA,IB,According to MDR Annex XV Chapter II. 2,2022-06-30
DE,Germany,Post-Market,CA,Synopsis,in DE. According to MDR Annex XV Chapter II. 1.11,2022-06-30
DE,Germany,Post-Market,CA,Description of the procedure,"A detailed description of the clinical procedures and diagnostic tests used during the course of the clinical investigation and, in particular, details of any deviations from usual practice",2022-06-30
DE,Germany,Post-Market,CA,The pre-clinical evaluation,According to MDR Annex XV Chapter II. 2.3,2022-06-30
DE,Germany,Post-Market,CA,IFU,Gebrauchsanweisung. According to MDR Annex XV Chapter II. 2.2,2022-06-30
DE,Germany,Post-Market,CA,Risk analysis,According to MDR Annex XV Chapter II. 2.5,2022-06-30
DE,Germany,Post-Market,CA,Signed statement for GSPRs,According to MDR Annex XV Chapter II. 4.1,2022-06-30
DE,Germany,Post-Market,CA,Follow-up plan,According to MDR Annex XV Chapter II. 3.16 ,2022-06-30
DE,Germany,Post-Market,CA,Power of Attorney for Representatives/ Vollmacht,According to MDR Annex XV Chapter II. 3.12,2022-06-30
DE,Germany,Post-Market,CA,Site sustainability,According to MDR Annex XV Chapter II. 1.13,2022-06-30
DE,Germany,Post-Market,CA,"PI Cvs, GCPs",,2022-06-30
DE,Germany,Post-Market,CA,"Other staffs Cvs, GCPs",,2022-06-30
DE,Germany,Post-Market,CA,Patient information & ICF,According to MDR Annex XV Chapter II. 4.4,2022-06-30
DE,Germany,Post-Market,CA,Justification Inclusion of particularly vulnerable groups,If aplicable ,2022-06-30
DE,Germany,Post-Market,CA,Proof of insurance,According to MDR Annex XV Chapter II. 4.5,2022-06-30
DE,Germany,Post-Market,CA,Subjects compensation,According to MDR Annex XV Chapter II. 3.1.4,2022-06-30
DE,Germany,Post-Market,CA,Data protection,,2022-06-30
DE,Germany,Post-Market,CA,CTA,,2022-06-30
DE,Germany,Post-Market,CA,Criteria and procedures for follow-up of subjects following the end of study,,2022-06-30
DE,Germany,Post-Market,CA,CEP,According to MDR Annex XV Chapter II. 3.18,2022-06-30
DE,Germany,Post-Market,CA,List  of technical documentation ,,2022-06-30
EE,Estonia,Pre-Market,CA,Application Form,Download from the webpage,2022-06-30
EE,Estonia,Pre-Market,CA,Study Protocol,,2022-06-30
EE,Estonia,Pre-Market,CA,Written information to subjects and consent form (s) for the subject.,,2022-06-30
EE,Estonia,Pre-Market,CA,"PI Cvs, GCPs",,2022-06-30
EE,Estonia,Pre-Market,CA,"CRF, questionnaires.",In Estonian,2022-06-30
EE,Estonia,Pre-Market,CA,Recruitment plan,In Estonian,2022-06-30
EE,Estonia,Pre-Market,CA,GDPR plan,,2022-06-30
EE,Estonia,Post-Market,CA,Application Form,Download from the webpage,2022-06-30
EE,Estonia,Post-Market,CA,Study Protocol,,2022-06-30
EE,Estonia,Post-Market,CA,Written information to subjects and consent form (s) for the subject.,,2022-06-30
EE,Estonia,Post-Market,CA,"PI Cvs, GCPs",,2022-06-30
EE,Estonia,Post-Market,CA,"CRF, questionnaires.",In Estonian,2022-06-30
EE,Estonia,Post-Market,CA,Recruitment plan,In Estonian,2022-06-30
EE,Estonia,Post-Market,CA,GDPR plan,,2022-06-30
ES,Spain,Pre-Market,CA,Cover Letter,,2022-06-30
ES,Spain,Pre-Market,CA,CIP ,"Acceptable in EN. Version, dated and signature",2022-06-30
ES,Spain,Pre-Market,CA,Synopsis,"in ES. Version, dated and sign.",2022-06-30
ES,Spain,Pre-Market,CA,Patient information and ICF,Version and date,2022-06-30
ES,Spain,Pre-Market,CA,Site sustainability,,2022-06-30
ES,Spain,Pre-Market,CA,"PI CVs, GCPs. ",PI name with 2 surnames,2022-06-30
ES,Spain,Pre-Market,CA,PI statement to compromise with the study.,PI name with 2 surnames,2022-06-30
ES,Spain,Pre-Market,CA,Study budget report,,2022-06-30
ES,Spain,Pre-Market,CA,Proof of Insurance ,,2022-06-30
ES,Spain,Pre-Market,CA,Recruitment Plan,,2022-06-30
ES,Spain,Pre-Market,CA,Sponsor statement ,,2022-06-30
ES,Spain,Post-Market,CA,Cover Letter,,2022-06-30
ES,Spain,Post-Market,CA,CIP ,"Acceptable in EN. Version, dated and signature",2022-06-30
ES,Spain,Post-Market,CA,Synopsis,"in ES. Version, dated and sign.",2022-06-30
ES,Spain,Post-Market,CA,Patient information and ICF,Version and date,2022-06-30
ES,Spain,Post-Market,CA,Site sustainability,,2022-06-30
ES,Spain,Post-Market,CA,"PI CVs, GCPs. ",PI name with 2 surnames,2022-06-30
ES,Spain,Post-Market,CA,PI statement to compromise with the study.,PI name with 2 surnames,2022-06-30
ES,Spain,Post-Market,CA,Study budget report,,2022-06-30
ES,Spain,Post-Market,CA,Proof of Insurance ,,2022-06-30
ES,Spain,Post-Market,CA,Recruitment Plan,,2022-06-30
ES,Spain,Post-Market,CA,Sponsor statement ,,2022-06-30
ES,Spain,Post-Market,CA,CE marking certification,,2022-06-30
FI,Finland,Pre-Market,CA,Cover Letter,,2022-06-30
FI,Finland,Pre-Market,CA,Synopsis,In Finnish,2022-06-30
FI,Finland,Pre-Market,CA,"Study on the ethics of research, including an assessment of the need for and relevance of research and a comparison of benefits and harms *",,2022-06-30
FI,Finland,Pre-Market,CA,Patient information,,2022-06-30
FI,Finland,Pre-Market,CA,ICF ,,2022-06-30
FI,Finland,Pre-Market,CA,Recruitment plan,,2022-06-30
FI,Finland,Pre-Market,CA,Other material to be provided to the subject,"questionnaires, patient diaries, recruitment notice, etc. material used for recruitment",2022-06-30
FI,Finland,Pre-Market,CA,Research plan,in EN,2022-06-30
FI,Finland,Pre-Market,CA,"Statement of qualifications of PI and his team. PI CV, GCP.",,2022-06-30
FI,Finland,Pre-Market,CA,Report on finance and detailed costs+ statement of possible conflicts of interest and interests,,2022-06-30
FI,Finland,Pre-Market,CA,Proof of insurance,,2022-06-30
FI,Finland,Pre-Market,CA,GDPR ,,2022-06-30
FI,Finland,Post-Market,CA,Cover Letter,,2022-06-30
FI,Finland,Post-Market,CA,Synopsis,In Finnish,2022-06-30
FI,Finland,Post-Market,CA,"Study on the ethics of research, including an assessment of the need for and relevance of research and a comparison of benefits and harms *",,2022-06-30
FI,Finland,Post-Market,CA,Patient information,,2022-06-30
FI,Finland,Post-Market,CA,ICF ,,2022-06-30
FI,Finland,Post-Market,CA,Recruitment plan,,2022-06-30
FI,Finland,Post-Market,CA,Other material to be provided to the subject,"questionnaires, patient diaries, recruitment notice, etc. material used for recruitment",2022-06-30
FI,Finland,Post-Market,CA,Research plan,in EN,2022-06-30
FI,Finland,Post-Market,CA,"Statement of qualifications of PI and his team. PI CV, GCP.",,2022-06-30
FI,Finland,Post-Market,CA,Report on finance and detailed costs+ statement of possible conflicts of interest and interests,,2022-06-30
FI,Finland,Post-Market,CA,Proof of insurance,,2022-06-30
FI,Finland,Post-Market,CA,GDPR ,,2022-06-30
FR,France,Pre-Market,CA,Main,,2022-06-30
FR,France,Pre-Market,CA,Application form (FAEC) ,,2022-06-30
FR,France,Pre-Market,CA,Clinical evaluation plan (CEP),,2022-06-30
FR,France,Pre-Market,CA,Instruction for use (IFU) for CE medical device used within or without the scope of its intended purpose,,2022-06-30
FR,France,Pre-Market,CA,Clinical investigation plan (PROTOCOLE),,2022-06-30
FR,France,Pre-Market,CA,Protocol synopsis (RESUME),,2022-06-30
FR,France,Pre-Market,CA,Other information (Please refer to Annex XV chap II 4),,2022-06-30
FR,France,Pre-Market,CA,Signed statement that the sponsor is aware that the competent authority may contact the ethics committee that is assessing or has assessed the application,,2022-06-30
FR,France,Pre-Market,CA,Proof of insurance (ASSURANCE) cover or indemnification of subjects in case of injury,,2022-06-30
FR,France,Pre-Market,CA,Documents to be used to obtain informed consent (NIFC),,2022-06-30
FR,France,Pre-Market,CA,"Patient Information form (including all written information to participants, and compensation of participants)",,2022-06-30
FR,France,Pre-Market,CA,Informed consent sheet,,2022-06-30
FR,France,Pre-Market,CA,Informed consent process,,2022-06-30
FR,France,Pre-Market,CA,"All the document used to recruit participants (letter to general practitioners, posters, explanatory booklets, websites, etc.) (RECRUTEMENT)",,2022-06-30
FR,France,Pre-Market,CA,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information (refer to annex XV chap II 4.5) (DONNEES),,2022-06-30
FR,France,Pre-Market,CA,Copy of the opinion of the Ethics Committee (CPP) if available (to be submitted as soon as available) (AVIS),,2022-06-30
FR,France,Pre-Market,CA,Technical file (DOSSIER_TECHNIQUE),,2022-06-30
FR,France,Pre-Market,CA,Statement of conformity: EC declaration of conformity or EU declaration of conformity ,,2022-06-30
FR,France,Pre-Market,CA,EC certificate,,2022-06-30
FR,France,Pre-Market,CA,Instructions for use for the clinical investigation ,,2022-06-30
FR,France,Pre-Market,CA,Other documents - National requirements (DOCUMENTS),,2022-06-30
FR,France,Pre-Market,CA,"Investigator list, proof of suitability of clinical investigators (LISTE_CV) and of suitability of investigational sites and investigational site team (EQUIPEMENT) ",,2022-06-30
FR,France,Pre-Market,CA,Import certificate for investigational medicinal products used in the IC ,,2022-06-30
FR,France,Pre-Market,CA,PMCF plan,,2022-06-30
FR,France,Post-Market,CA,Main,,2022-06-30
FR,France,Post-Market,CA,Application form (FAEC) ,,2022-06-30
FR,France,Post-Market,CA,Clinical evaluation plan (CEP),,2022-06-30
FR,France,Post-Market,CA,Instruction for use (IFU) for CE medical device used within or without the scope of its intended purpose,,2022-06-30
FR,France,Post-Market,CA,Clinical investigation plan (PROTOCOLE),,2022-06-30
FR,France,Post-Market,CA,Protocol synopsis (RESUME),,2022-06-30
FR,France,Post-Market,CA,Other information (Please refer to Annex XV chap II 4),,2022-06-30
FR,France,Post-Market,CA,Signed statement that the sponsor is aware that the competent authority may contact the ethics committee that is assessing or has assessed the application,,2022-06-30
FR,France,Post-Market,CA,Proof of insurance (ASSURANCE) cover or indemnification of subjects in case of injury,,2022-06-30
FR,France,Post-Market,CA,Documents to be used to obtain informed consent (NIFC),,2022-06-30
FR,France,Post-Market,CA,"Patient Information form (including all written information to participants, and compensation of participants)",,2022-06-30
FR,France,Post-Market,CA,Informed consent sheet,,2022-06-30
FR,France,Post-Market,CA,Informed consent process,,2022-06-30
FR,France,Post-Market,CA,"All the document used to recruit participants (letter to general practitioners, posters, explanatory booklets, websites, etc.) (RECRUTEMENT)",,2022-06-30
FR,France,Post-Market,CA,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information (refer to annex XV chap II 4.5) (DONNEES),,2022-06-30
FR,France,Post-Market,CA,Copy of the opinion of the Ethics Committee (CPP) if available (to be submitted as soon as available) (AVIS),,2022-06-30
FR,France,Post-Market,CA,Technical file (DOSSIER_TECHNIQUE),,2022-06-30
FR,France,Post-Market,CA,Statement of conformity: EC declaration of conformity or EU declaration of conformity ,,2022-06-30
FR,France,Post-Market,CA,EC certificate,,2022-06-30
FR,France,Post-Market,CA,Instructions for use for the clinical investigation ,,2022-06-30
FR,France,Post-Market,CA,Other documents - National requirements (DOCUMENTS),,2022-06-30
FR,France,Post-Market,CA,"Investigator list, proof of suitability of clinical investigators (LISTE_CV) and of suitability of investigational sites and investigational site team (EQUIPEMENT) ",,2022-06-30
FR,France,Post-Market,CA,Import certificate for investigational medicinal products used in the IC ,,2022-06-30
FR,France,Post-Market,CA,PMCF plan,,2022-06-30
GK,Grece,Pre-Market,CA,I. Cover letter which will include a list of contents,,2022-06-30
GK,Grece,Pre-Market,CA,"II. General Part: The documentation to be included in the General Part of the filing file to the EOF is set out in Annex XV, Chapter II of Regulation (EU) 2017/745.",,2022-06-30
GK,Grece,Pre-Market,CA,Application Form,,2022-06-30
GK,Grece,Pre-Market,CA,Investigator Brochure (IB),,2022-06-30
GK,Grece,Pre-Market,CA,Clinical Investigation Plan (CIP),,2022-06-30
GK,Grece,Pre-Market,CA,Compliance statement letter,,2022-06-30
GK,Grece,Pre-Market,CA,Insurance certificate,,2022-06-30
GK,Grece,Pre-Market,CA,Patient informed consent form (ICF),,2022-06-30
GK,Grece,Pre-Market,CA,Data confidentiality letter,,2022-06-30
GK,Grece,Pre-Market,CA,Instruction for use (IFU),,2022-06-30
GK,Grece,Pre-Market,CA,Case report form (CRF),,2022-06-30
GK,Grece,Pre-Market,CA,"III. Special Part: In addition to the supporting documents of the General Part, the file to the EOF will include the following Special supporting documents:",,2022-06-30
GK,Grece,Pre-Market,CA,"Completed the application form in Greek (available on the EOF website), in searchable pdf format, with signature, signatory details and date  ",,2022-06-30
GK,Grece,Pre-Market,CA,"General Summary of the clinical investigation plan (SYNOPSIS) in the Greek language (Relative to Section 3.1.5 of Reg. 2017/745, Par. XV, Chapter II)",,2022-06-30
GK,Grece,Pre-Market,CA,"Patient information and consent form (s), in Greek (& original in English if available). ",,2022-06-30
GK,Grece,Pre-Market,CA,Agreement PI & Sponsor,,2022-06-30
GK,Grece,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
GK,Grece,Pre-Market,CA,"If the applicant is not the sponsor, a letter of authorization to the applicant to act on behalf of the sponsor.",,2022-06-30
GK,Grece,Pre-Market,CA,CE marking certificate (if aplicable),,2022-06-30
GK,Grece,Pre-Market,CA,"Model of the label in the Greek language in which there will be, among other information, the labeling ""exclusively for clinical trials"".",,2022-06-30
GK,Grece,Pre-Market,CA,"Responsible statement from the sponsor stating whether the product contains as an integral part of the substance or derivative of human blood (in addition to Point 2.6 of Reg. 2017/745, Par. XV, Chapter II).",,2022-06-30
GK,Grece,Pre-Market,CA,Proof of payment of a fee in favor of EOF,,2022-06-30
GK,Grece,Pre-Market,CA,Study Budget,,2022-06-30
GK,Grece,Post-Market,CA,I. Cover letter which will include a list of contents,,2022-06-30
GK,Grece,Post-Market,CA,"II. General Part: The documentation to be included in the General Part of the filing file to the EOF is set out in Annex XV, Chapter II of Regulation (EU) 2017/745.",,2022-06-30
GK,Grece,Post-Market,CA,Application Form,,2022-06-30
GK,Grece,Post-Market,CA,Investigator Brochure (IB),,2022-06-30
GK,Grece,Post-Market,CA,Clinical Investigation Plan (CIP),,2022-06-30
GK,Grece,Post-Market,CA,Compliance statement letter,,2022-06-30
GK,Grece,Post-Market,CA,Insurance certificate,,2022-06-30
GK,Grece,Post-Market,CA,Patient informed consent form (ICF),,2022-06-30
GK,Grece,Post-Market,CA,Data confidentiality letter,,2022-06-30
GK,Grece,Post-Market,CA,Instruction for use (IFU),,2022-06-30
GK,Grece,Post-Market,CA,Case report form (CRF),,2022-06-30
GK,Grece,Post-Market,CA,"III. Special Part: In addition to the supporting documents of the General Part, the file to the EOF will include the following Special supporting documents:",,2022-06-30
GK,Grece,Post-Market,CA,"Completed the application form in Greek (available on the EOF website), in searchable pdf format, with signature, signatory details and date  ",,2022-06-30
GK,Grece,Post-Market,CA,"General Summary of the clinical investigation plan (SYNOPSIS) in the Greek language (Relative to Section 3.1.5 of Reg. 2017/745, Par. XV, Chapter II)",,2022-06-30
GK,Grece,Post-Market,CA,"Patient information and consent form (s), in Greek (& original in English if available). ",,2022-06-30
GK,Grece,Post-Market,CA,Agreement PI & Sponsor,,2022-06-30
GK,Grece,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
GK,Grece,Post-Market,CA,"If the applicant is not the sponsor, a letter of authorization to the applicant to act on behalf of the sponsor.",,2022-06-30
GK,Grece,Post-Market,CA,CE marking certificate (if aplicable),,2022-06-30
GK,Grece,Post-Market,CA,"Model of the label in the Greek language in which there will be, among other information, the labeling ""exclusively for clinical trials"".",,2022-06-30
GK,Grece,Post-Market,CA,"Responsible statement from the sponsor stating whether the product contains as an integral part of the substance or derivative of human blood (in addition to Point 2.6 of Reg. 2017/745, Par. XV, Chapter II).",,2022-06-30
GK,Grece,Post-Market,CA,Proof of payment of a fee in favor of EOF,,2022-06-30
GK,Grece,Post-Market,CA,Study Budget,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Cover Letter,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Application Form ,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,CIP,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Synopsis,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Patient Consent Statement (ICF),,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,The Declaration of Compliance with the Declaration of Helsinki ,Download from the website,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,"CVs, GCPs of PI",,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,"List of publications of the supervisor and participants in the research, if not included in the MTMT database. ","(Please indicate A letter of intent from the study director or coordinating study director, in which he or she undertakes to carry out the study Letter (s) of support from the head (s) of the institution - statement (s) of acceptance",2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Privacy/Confidentiality statement ,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Institutional liability insurance in the case of an intervention investigation.,,2022-06-30
HR,Croatia (local name: Hrvatska),Pre-Market,CA,Proof of payment of the service fee.,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Cover Letter,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Application Form ,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,CIP,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Synopsis,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Patient Consent Statement (ICF),,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,The Declaration of Compliance with the Declaration of Helsinki ,Download from the website,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,"CVs, GCPs of PI",,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,"List of publications of the supervisor and participants in the research, if not included in the MTMT database. ","(Please indicate A letter of intent from the study director or coordinating study director, in which he or she undertakes to carry out the study Letter (s) of support from the head (s) of the institution - statement (s) of acceptance",2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Privacy/Confidentiality statement ,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Institutional liability insurance in the case of an intervention investigation.,,2022-06-30
HR,Croatia (local name: Hrvatska),Post-Market,CA,Proof of payment of the service fee.,,2022-06-30
IE,Ireland,Pre-Market,CA,Application Form,Download from webpage,2022-06-30
IE,Ireland,Pre-Market,CA,Checklist form ,Download from webpage,2022-06-30
IE,Ireland,Pre-Market,CA,Fee payment form,https://www.nrecoffice.ie/apply-2/fees/,2022-06-30
IE,Ireland,Pre-Market,CA,Cover Letter,Headed paper,2022-06-30
IE,Ireland,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
IE,Ireland,Pre-Market,CA,Patient information and ICF,,2022-06-30
IE,Ireland,Pre-Market,CA,Proof of insurance,,2022-06-30
IE,Ireland,Pre-Market,CA,Site sustainability form,,2022-06-30
IE,Ireland,Pre-Market,CA,GDPR ,,2022-06-30
IE,Ireland,Pre-Market,CA,Details of any Data Monitoring Committee,If aplicable,2022-06-30
IE,Ireland,Pre-Market,CA,GSPR signed statement,,2022-06-30
IE,Ireland,Pre-Market,CA,Letter from Sponsor,,2022-06-30
IE,Ireland,Pre-Market,CA,CRF,,2022-06-30
IE,Ireland,Pre-Market,CA,Recruitment plan,,2022-06-30
IE,Ireland,Pre-Market,CA,CIP,,2022-06-30
IE,Ireland,Pre-Market,CA,IB,,2022-06-30
IE,Ireland,Post-Market,CA,Application Form,Download from webpage,2022-06-30
IE,Ireland,Post-Market,CA,Checklist form ,Download from webpage,2022-06-30
IE,Ireland,Post-Market,CA,Fee payment form,https://www.nrecoffice.ie/apply-2/fees/,2022-06-30
IE,Ireland,Post-Market,CA,Cover Letter,Headed paper,2022-06-30
IE,Ireland,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
IE,Ireland,Post-Market,CA,Patient information and ICF,,2022-06-30
IE,Ireland,Post-Market,CA,Proof of insurance,,2022-06-30
IE,Ireland,Post-Market,CA,Site sustainability form,,2022-06-30
IE,Ireland,Post-Market,CA,GDPR ,,2022-06-30
IE,Ireland,Post-Market,CA,Details of any Data Monitoring Committee,If aplicable,2022-06-30
IE,Ireland,Post-Market,CA,GSPR signed statement,,2022-06-30
IE,Ireland,Post-Market,CA,Letter from Sponsor,,2022-06-30
IE,Ireland,Post-Market,CA,CRF,,2022-06-30
IE,Ireland,Post-Market,CA,Recruitment plan,,2022-06-30
IE,Ireland,Post-Market,CA,CIP,,2022-06-30
IE,Ireland,Post-Market,CA,IB,,2022-06-30
IT,Italy,Pre-Market,CA,"Letter from the sponsor requesting an opinion for the study (specify the title, duration and specific type of the study)",,2022-06-30
IT,Italy,Pre-Market,CA,"Letter of proxy from the Sponsor, if the CRO is present= Sponsor delegation of authority",,2022-06-30
IT,Italy,Pre-Market,CA,Single and definitive opinion of the Coordinating Center Ethics Committee limited to observational studies of prospective and drug cohort,,2022-06-30
IT,Italy,Pre-Market,CA,Complete study protocol and any amendments with version and date on each page (CIP),,2022-06-30
IT,Italy,Pre-Market,CA,Synopsis of the protocol in Italian (indicate version of the protocol),,2022-06-30
IT,Italy,Pre-Market,CA,Patient Information Form with version and date on each page,,2022-06-30
IT,Italy,Pre-Market,CA,ICF (indicate the version),,2022-06-30
IT,Italy,Pre-Market,CA,Information and consent form for the processing of personal data (download from Webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Statement by the Coordinator on the observational nature of the study,,2022-06-30
IT,Italy,Pre-Market,CA,"Details regarding the manager, the staff and the location where the study will take place",,2022-06-30
IT,Italy,Pre-Market,CA,List of participating centers dated and with protocol version,,2022-06-30
IT,Italy,Pre-Market,CA," ""Contract for conducting clinical trials on medicines"" Form (Download)",,2022-06-30
IT,Italy,Pre-Market,CA,List of information to be collected,,2022-06-30
IT,Italy,Pre-Market,CA,Declaration of cost coverage,,2022-06-30
IT,Italy,Pre-Market,CA,Identification of funding sources,,2022-06-30
IT,Italy,Pre-Market,CA,Investigator’s CVs dated and signed,,2022-06-30
IT,Italy,Pre-Market,CA,Investigator's application dated and signed,,2022-06-30
IT,Italy,Pre-Market,CA,"If the study is sponsored, receipt of the transfer or declaration from the Promoter in the case of a non-profit study",,2022-06-30
IT,Italy,Pre-Market,CA,EC documents list,,2022-06-30
IT,Italy,Pre-Market,CA,"Please submit the following application in this way: Send a hard copy and an electronic copy (cd-rom) of the documents listed below to the Secretariat Office of the Ethics Committee, Pav. 3 - New Entrance Careggi (NIC) - Didactics - Largo Brambilla, 3 - 50134 Florence",Region Toscana: https://www.aou-careggi.toscana.it/internet/index.php?option=com_content&view=article&id=4385&Itemid=962&lang=it,2022-06-30
IT,Italy,Pre-Market,CA,Documents ,Note,2022-06-30
IT,Italy,Pre-Market,CA,Letter of Intent (Form in webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Synopsis in Italian (Form in webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Complete study protocol and any amendments with version and date on each page (CIP),,2022-06-30
IT,Italy,Pre-Market,CA,List of participating sites,,2022-06-30
IT,Italy,Pre-Market,CA,Data collection information (CRF),,2022-06-30
IT,Italy,Pre-Market,CA,Insurance certificate in Italian (if applicable),,2022-06-30
IT,Italy,Pre-Market,CA,Receipt of the payment of the amount established by the Tuscany Region for the examination of the study protocol,,2022-06-30
IT,Italy,Pre-Market,CA,Economic agreement (Form on webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Informed Consent Form in Italian (Form on webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Device user manual = IFU?,,2022-06-30
IT,Italy,Pre-Market,CA,CE Marking Certification ,,2022-06-30
IT,Italy,Pre-Market,CA,Device Preliminary CheckList (Form in webpage),CHECK if the device has registered in Italy. https://www.salute.gov.it/interrogazioneDispositivi/RicercaDispositiviServlet?action=ACTION_MASCHERA ,2022-06-30
IT,Italy,Pre-Market,CA,PI Acceptance Form (on webpage),,2022-06-30
IT,Italy,Pre-Market,CA,"PI CVs, GCPs.. Up to date",,2022-06-30
IT,Italy,Pre-Market,CA,Feasibility Assessment (Form on webpage),,2022-06-30
IT,Italy,Pre-Market,CA,Public Statement on Local Investigator's Conflict of Interest (Form on webpage),,2022-06-30
IT,Italy,Post-Market,CA,"Letter from the sponsor requesting an opinion for the study (specify the title, duration and specific type of the study)",,2022-06-30
IT,Italy,Post-Market,CA,"Letter of proxy from the Sponsor, if the CRO is present= Sponsor delegation of authority",,2022-06-30
IT,Italy,Post-Market,CA,Single and definitive opinion of the Coordinating Center Ethics Committee limited to observational studies of prospective and drug cohort,,2022-06-30
IT,Italy,Post-Market,CA,Complete study protocol and any amendments with version and date on each page (CIP),,2022-06-30
IT,Italy,Post-Market,CA,Synopsis of the protocol in Italian (indicate version of the protocol),,2022-06-30
IT,Italy,Post-Market,CA,Patient Information Form with version and date on each page,,2022-06-30
IT,Italy,Post-Market,CA,ICF (indicate the version),,2022-06-30
IT,Italy,Post-Market,CA,Information and consent form for the processing of personal data (download from Webpage),,2022-06-30
IT,Italy,Post-Market,CA,Statement by the Coordinator on the observational nature of the study,,2022-06-30
IT,Italy,Post-Market,CA,"Details regarding the manager, the staff and the location where the study will take place",,2022-06-30
IT,Italy,Post-Market,CA,List of participating centers dated and with protocol version,,2022-06-30
IT,Italy,Post-Market,CA," ""Contract for conducting clinical trials on medicines"" Form (Download)",,2022-06-30
IT,Italy,Post-Market,CA,List of information to be collected,,2022-06-30
IT,Italy,Post-Market,CA,Declaration of cost coverage,,2022-06-30
IT,Italy,Post-Market,CA,Identification of funding sources,,2022-06-30
IT,Italy,Post-Market,CA,Investigator’s CVs dated and signed,,2022-06-30
IT,Italy,Post-Market,CA,Investigator's application dated and signed,,2022-06-30
IT,Italy,Post-Market,CA,"If the study is sponsored, receipt of the transfer or declaration from the Promoter in the case of a non-profit study",,2022-06-30
LT,Lithuania,Pre-Market,CA,Application Form,Download from web,2022-06-30
LT,Lithuania,Pre-Market,CA,CEP,,2022-06-30
LT,Lithuania,Pre-Market,CA,Synopsis,,2022-06-30
LT,Lithuania,Pre-Market,CA,Information on whether the medical device contains a medicinal substance,If aplicable,2022-06-30
LT,Lithuania,Pre-Market,CA,Information on the comparator,If aplicable,2022-06-30
LT,Lithuania,Pre-Market,CA,Sponsor statement on Site sustainability,,2022-06-30
LT,Lithuania,Pre-Market,CA,Statement of GSPRs ,,2022-06-30
LT,Lithuania,Pre-Market,CA,IB,,2022-06-30
LT,Lithuania,Pre-Market,CA,CIP,,2022-06-30
LT,Lithuania,Pre-Market,CA,Proof of insurance,,2022-06-30
LT,Lithuania,Pre-Market,CA,Patient information & ICF,,2022-06-30
LT,Lithuania,Pre-Market,CA,Statement of Data Protection ,,2022-06-30
LT,Lithuania,Post-Market,CA,Application Form,Download from web,2022-06-30
LT,Lithuania,Post-Market,CA,CEP,,2022-06-30
LT,Lithuania,Post-Market,CA,Synopsis,,2022-06-30
LT,Lithuania,Post-Market,CA,Information on whether the medical device contains a medicinal substance,If aplicable,2022-06-30
LT,Lithuania,Post-Market,CA,Information on the comparator,If aplicable,2022-06-30
LT,Lithuania,Post-Market,CA,Sponsor statement on Site sustainability,,2022-06-30
LT,Lithuania,Post-Market,CA,Statement of GSPRs ,,2022-06-30
LT,Lithuania,Post-Market,CA,IB,,2022-06-30
LT,Lithuania,Post-Market,CA,CIP,,2022-06-30
LT,Lithuania,Post-Market,CA,Proof of insurance,,2022-06-30
LT,Lithuania,Post-Market,CA,Patient information & ICF,,2022-06-30
LT,Lithuania,Post-Market,CA,Statement of Data Protection ,,2022-06-30
LU,Luxembourg,Pre-Market,CA,Instruction (see note),The Competent Authority is in charge of sending the correspondence documents to the EC. ,2022-06-30
LU,Luxembourg,Post-Market,CA,Instruction (see note),The Competent Authority is in charge of sending the correspondence documents to the EC. ,2022-06-30
LV,Latvia,Pre-Market,CA,Protocols,,2022-06-30
LV,Latvia,Pre-Market,CA,Synopsis,,2022-06-30
LV,Latvia,Pre-Market,CA,the description of measures for involvement of the trial subjects,Recruitment plan,2022-06-30
LV,Latvia,Pre-Market,CA,Aplication Form,Paragraph 63 Regulation No. 891 ,2022-06-30
LV,Latvia,Pre-Market,CA,the documentation specifying whether compensation related to the participation in the trial is anticipated for the trial subject,,2022-06-30
LV,Latvia,Pre-Market,CA,Patient Information and ICF,,2022-06-30
LV,Latvia,Pre-Market,CA,Proof of payment,,2022-06-30
LV,Latvia,Pre-Market,CA,a power of attorney issued by the manufacturer if the documents are submitted by his or her authorized representative (the manufacturer shall ensure that his or her authorized representative is registered in a Member State of the European Union or a country of the European Economic Area),,2022-06-30
LV,Latvia,Pre-Market,CA,Proof of insurance,,2022-06-30
LV,Latvia,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
LV,Latvia,Pre-Market,CA,Risk analysis,,2022-06-30
LV,Latvia,Pre-Market,CA,NOTE,"Meetings of the Ethics Committee take place on the 1st Thursday of the month, applications must be submitted no later than 5 working days in advance.",2022-06-30
LV,Latvia,Post-Market,CA,Protocols,,2022-06-30
LV,Latvia,Post-Market,CA,Synopsis,,2022-06-30
LV,Latvia,Post-Market,CA,the description of measures for involvement of the trial subjects,Recruitment plan,2022-06-30
LV,Latvia,Post-Market,CA,Aplication Form,Paragraph 63 Regulation No. 891 ,2022-06-30
LV,Latvia,Post-Market,CA,the documentation specifying whether compensation related to the participation in the trial is anticipated for the trial subject,,2022-06-30
LV,Latvia,Post-Market,CA,Patient Information and ICF,,2022-06-30
LV,Latvia,Post-Market,CA,Proof of payment,,2022-06-30
LV,Latvia,Post-Market,CA,a power of attorney issued by the manufacturer if the documents are submitted by his or her authorized representative (the manufacturer shall ensure that his or her authorized representative is registered in a Member State of the European Union or a country of the European Economic Area),,2022-06-30
LV,Latvia,Post-Market,CA,Proof of insurance,,2022-06-30
LV,Latvia,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
LV,Latvia,Post-Market,CA,Risk analysis,,2022-06-30
LV,Latvia,Post-Market,CA,NOTE,"Meetings of the Ethics Committee take place on the 1st Thursday of the month, applications must be submitted no later than 5 working days in advance.",2022-06-30
MT,Malta,Pre-Market,CA,Protocol,,2022-06-30
MT,Malta,Pre-Market,CA,Risk analysis ,,2022-06-30
MT,Malta,Pre-Market,CA,"PI CVs, GCP",,2022-06-30
MT,Malta,Pre-Market,CA,IB,,2022-06-30
MT,Malta,Pre-Market,CA,Site sustainabilities,,2022-06-30
MT,Malta,Pre-Market,CA,Patient information and ICF ,,2022-06-30
MT,Malta,Pre-Market,CA,Indemnity/compensation if needed,,2022-06-30
MT,Malta,Pre-Market,CA,Proof of insurance ,,2022-06-30
MT,Malta,Pre-Market,CA,Agreements between sponsor/PI/hospitals,,2022-06-30
MT,Malta,Pre-Market,CA,Recruitment plan,,2022-06-30
MT,Malta,Post-Market,CA,Protocol,,2022-06-30
MT,Malta,Post-Market,CA,Risk analysis ,,2022-06-30
MT,Malta,Post-Market,CA,"PI CVs, GCP",,2022-06-30
MT,Malta,Post-Market,CA,IB,,2022-06-30
MT,Malta,Post-Market,CA,Site sustainabilities,,2022-06-30
MT,Malta,Post-Market,CA,Patient information and ICF ,,2022-06-30
MT,Malta,Post-Market,CA,Indemnity/compensation if needed,,2022-06-30
MT,Malta,Post-Market,CA,Proof of insurance ,,2022-06-30
MT,Malta,Post-Market,CA,Agreements between sponsor/PI/hospitals,,2022-06-30
MT,Malta,Post-Market,CA,Recruitment plan,,2022-06-30
NL,Netherlands,Pre-Market,CA,A1. Cover Letter,Download template,2022-06-30
NL,Netherlands,Pre-Market,CA,A2. Authorization form the sponsor OR Authorisation from legal representative EU if sponsor does not hold offices within EU,,2022-06-30
NL,Netherlands,Pre-Market,CA,B1. Application Form,complete the ABR form in ToetsingOnline. https://english.ccmo.nl/investigators/clinical-investigations-with-medical-devices/standard-research-file-medical-devices/b-forms/b1-abr-form,2022-06-30
NL,Netherlands,Pre-Market,CA,B2. Eudamed registration,,2022-06-30
NL,Netherlands,Pre-Market,CA,C1. Protocols (CIP),,2022-06-30
NL,Netherlands,Pre-Market,CA,C2. CIP amendments,if aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,D1. IB ,,2022-06-30
NL,Netherlands,Pre-Market,CA,D2. Investiogational MD Dossier (IMDD),,2022-06-30
NL,Netherlands,Pre-Market,CA,D3. Manufacturer statement on safety and performances,,2022-06-30
NL,Netherlands,Pre-Market,CA,E1/E2a. Template Subject Information Sheet for research subjects <16 years of age (children) (if aplicable to the study),"The templates are updated regularly. At all times, use the most recent versions of the templates as available on this website.",2022-06-30
NL,Netherlands,Pre-Market,CA,E1/E2b. Template Subject Information Sheet for research subjects > 16 years of age (adults),,2022-06-30
NL,Netherlands,Pre-Market,CA,E3. Promotional materials research subjects,If aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,E4. Other informational materials,If aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,E5. Newsletters or letters with study results,If aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,F1. Questionnaire. F2 Patient Diaries. F3. Patient cards. F4. Other ,If aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,G1. Proof of insurance,,2022-06-30
NL,Netherlands,Pre-Market,CA,G2. Proof of coverage,,2022-06-30
NL,Netherlands,Pre-Market,CA,"H2. PI Cv, GCP",,2022-06-30
NL,Netherlands,Pre-Market,CA,I1. List of participating centers,,2022-06-30
NL,Netherlands,Pre-Market,CA,I2. Site sustainability,,2022-06-30
NL,Netherlands,Pre-Market,CA,"I3. Centers PI CVs, GCPs",,2022-06-30
NL,Netherlands,Pre-Market,CA,J1. Financial compensation for research subjects,This is only applicable when the information in the ABR form is not sufficient.,2022-06-30
NL,Netherlands,Pre-Market,CA,J2. Financial compensation for investigators and participating centres,This is only applicable when the information in the ABR form is not sufficient.,2022-06-30
NL,Netherlands,Pre-Market,CA,K1. Recommendations other authorities,If aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,K2. Assessment other EU member states,If aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,K3. Clinical trial agreements,If aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,K4. Scientific publications,If aplicable,2022-06-30
NL,Netherlands,Pre-Market,CA,K5. Data Safety Monitoring Board (DSMB),If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,A1. Cover Letter,Download template,2022-06-30
NL,Netherlands,Post-Market,CA,A2. Authorization form the sponsor OR Authorisation from legal representative EU if sponsor does not hold offices within EU,,2022-06-30
NL,Netherlands,Post-Market,CA,B1. Application Form,complete the ABR form in ToetsingOnline. https://english.ccmo.nl/investigators/clinical-investigations-with-medical-devices/standard-research-file-medical-devices/b-forms/b1-abr-form,2022-06-30
NL,Netherlands,Post-Market,CA,B2. Eudamed registration,,2022-06-30
NL,Netherlands,Post-Market,CA,C1. Protocols (CIP),,2022-06-30
NL,Netherlands,Post-Market,CA,C2. CIP amendments,if aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,D1. IB or D2. IFU,Just one option,2022-06-30
NL,Netherlands,Post-Market,CA,D3. Manufacturer statement on safety and performances,,2022-06-30
NL,Netherlands,Post-Market,CA,E1/E2a. Template Subject Information Sheet for research subjects <16 years of age (children) (if aplicable to the study),"The templates are updated regularly. At all times, use the most recent versions of the templates as available on this website.",2022-06-30
NL,Netherlands,Post-Market,CA,E1/E2b. Template Subject Information Sheet for research subjects > 16 years of age (adults),,2022-06-30
NL,Netherlands,Post-Market,CA,E3. Promotional materials research subjects,If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,E4. Other informational materials,If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,E5. Newsletters or letters with study results,If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,F1. Questionnaire. F2 Patient Diaries. F3. Patient cards. F4. Other ,If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,G1. Proof of insurance,,2022-06-30
NL,Netherlands,Post-Market,CA,G2. Proof of coverage,,2022-06-30
NL,Netherlands,Post-Market,CA,"H2. PI Cv, GCP",,2022-06-30
NL,Netherlands,Post-Market,CA,I1. List of participating centers,,2022-06-30
NL,Netherlands,Post-Market,CA,I2. Site sustainability,,2022-06-30
NL,Netherlands,Post-Market,CA,"I3. Centers PI CVs, GCPs",,2022-06-30
NL,Netherlands,Post-Market,CA,J1. Financial compensation for research subjects,This is only applicable when the information in the ABR form is not sufficient.,2022-06-30
NL,Netherlands,Post-Market,CA,J2. Financial compensation for investigators and participating centres,This is only applicable when the information in the ABR form is not sufficient.,2022-06-30
NL,Netherlands,Post-Market,CA,K1. Recommendations other authorities,If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,K2. Assessment other EU member states,If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,K3. Clinical trial agreements,If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,K4. Scientific publications,If aplicable,2022-06-30
NL,Netherlands,Post-Market,CA,K5. Data Safety Monitoring Board (DSMB),If aplicable,2022-06-30
NO,Norway,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
NO,Norway,Pre-Market,CA,Research protocol,,2022-06-30
NO,Norway,Pre-Market,CA,IB,,2022-06-30
NO,Norway,Pre-Market,CA,EudraCT form,,2022-06-30
NO,Norway,Pre-Market,CA,Questionnaire,,2022-06-30
NO,Norway,Pre-Market,CA,Interview guide,,2022-06-30
NO,Norway,Pre-Market,CA,Information sheet for children,If aplicable,2022-06-30
NO,Norway,Pre-Market,CA,Request for participation and consent declaration for parents where research is conducted on minors,If aplicable,2022-06-30
NO,Norway,Pre-Market,CA,Request for participation and consent declaration for adults,,2022-06-30
NO,Norway,Pre-Market,CA,IFU,,2022-06-30
NO,Norway,Pre-Market,CA,CIP,,2022-06-30
NO,Norway,Pre-Market,CA,Synopsis,,2022-06-30
NO,Norway,Pre-Market,CA,Data protection,,2022-06-30
NO,Norway,Pre-Market,CA,Risk analysis,,2022-06-30
NO,Norway,Pre-Market,CA,Proof of insurance,,2022-06-30
NO,Norway,Pre-Market,CA,NOTE,"As a rule, applications must be written in Norwegian. If the project is to be carried out in its entirety abroad, the application can be made in English. Files uploaded must be in PDF format (Adobe acrobat)",2022-06-30
NO,Norway,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
NO,Norway,Post-Market,CA,Research protocol,,2022-06-30
NO,Norway,Post-Market,CA,IB,,2022-06-30
NO,Norway,Post-Market,CA,EudraCT form,,2022-06-30
NO,Norway,Post-Market,CA,Questionnaire,,2022-06-30
NO,Norway,Post-Market,CA,Interview guide,,2022-06-30
NO,Norway,Post-Market,CA,Information sheet for children,If aplicable,2022-06-30
NO,Norway,Post-Market,CA,Request for participation and consent declaration for parents where research is conducted on minors,If aplicable,2022-06-30
NO,Norway,Post-Market,CA,Request for participation and consent declaration for adults,,2022-06-30
NO,Norway,Post-Market,CA,CE certificate,,2022-06-30
NO,Norway,Post-Market,CA,IFU,,2022-06-30
NO,Norway,Post-Market,CA,CIP,,2022-06-30
NO,Norway,Post-Market,CA,Synopsis,,2022-06-30
NO,Norway,Post-Market,CA,Data protection,,2022-06-30
NO,Norway,Post-Market,CA,Risk analysis,,2022-06-30
NO,Norway,Post-Market,CA,Proof of insurance,,2022-06-30
NO,Norway,Post-Market,CA,NOTE,"As a rule, applications must be written in Norwegian. If the project is to be carried out in its entirety abroad, the application can be made in English. Files uploaded must be in PDF format (Adobe acrobat)",2022-06-30
PT,Portugal,Pre-Market,CA,1.1.1 - Request,Annex I. https://www.ceic.pt/formularios,2022-06-30
PT,Portugal,Pre-Market,CA,1.1.2 - Letter of Representation signed by the promoter (manufacturer or other),,2022-06-30
PT,Portugal,Pre-Market,CA,"1.1.3 - List of Competent Authorities of the Member States involved, to which the request was submitted.",,2022-06-30
PT,Portugal,Pre-Market,CA,1.1.4 - Opinions of the Ethics Commissions of the Member States involved.,,2022-06-30
PT,Portugal,Pre-Market,CA,1.1.5 - Declaration of conformity,,2022-06-30
PT,Portugal,Pre-Market,CA,1.1.6 - Form for notification related to medical devices intended for clinical investigation,,2022-06-30
PT,Portugal,Pre-Market,CA,1.1.7- Proof of payment ,,2022-06-30
PT,Portugal,Pre-Market,CA,"1.2.1.1.1 - CIF (Informed Consent Form and
Information Leaflet)",,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.1.1.2 - Patient card,,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.1.1.3 – Information about the contact person,,2022-06-30
PT,Portugal,Pre-Market,CA,"Recruiment Mode, Publicity Material, Questionnaires",1.2.1.2; 1.2.1.3; 1.2.1.4 respectively,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.2.1 - Declaration of the conditions of the center for carrying out the study,Site sustainability,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.2.2 - Declaration of the DM circuit,,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.3.1.1 – CV of the Coordinating Investigator,,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.3.1.2 – CV of Principal Investigators,,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.4.1 - Insurance and Indemnities,,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.4.2 - Compensation/payments to Participants,,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.4.3 - Contracts,,2022-06-30
PT,Portugal,Pre-Market,CA,1.2.4.3.1 - Study centers,,2022-06-30
PT,Portugal,Pre-Market,CA,2.1. – Clinical investigation plan + amandments,,2022-06-30
PT,Portugal,Pre-Market,CA,2.2 - Synopsis ,in Portuguese,2022-06-30
PT,Portugal,Pre-Market,CA,2.3.1 - Clinical Trials with the same DM(s),optional,2022-06-30
PT,Portugal,Pre-Market,CA,2.3.2 - Scientific Assessment,if aplicable,2022-06-30
PT,Portugal,Pre-Market,CA,2.3.3 - Ethical Assessment,if aplicable,2022-06-30
PT,Portugal,Pre-Market,CA,3.1 – Investigator’s Brochure,In case of pre-market,2022-06-30
PT,Portugal,Post-Market,CA,1.1.1 - Request,Annex I. https://www.ceic.pt/formularios,2022-06-30
PT,Portugal,Post-Market,CA,1.1.2 - Letter of Representation signed by the promoter (manufacturer or other),,2022-06-30
PT,Portugal,Post-Market,CA,"1.1.3 - List of Competent Authorities of the Member States involved, to which the request was submitted.",,2022-06-30
PT,Portugal,Post-Market,CA,1.1.4 - Opinions of the Ethics Commissions of the Member States involved.,,2022-06-30
PT,Portugal,Post-Market,CA,1.1.5 - Declaration of conformity,,2022-06-30
PT,Portugal,Post-Market,CA,CE certificate,PMCF,2022-06-30
PT,Portugal,Post-Market,CA,Labeling,PMCF,2022-06-30
PT,Portugal,Post-Market,CA,IFU ,PMCF,2022-06-30
PT,Portugal,Post-Market,CA,1.1.6 - Form for notification related to medical devices intended for clinical investigation,,2022-06-30
PT,Portugal,Post-Market,CA,1.1.7- Proof of payment ,,2022-06-30
PT,Portugal,Post-Market,CA,"1.2.1.1.1 - CIF (Informed Consent Form and
Information Leaflet)",,2022-06-30
PT,Portugal,Post-Market,CA,1.2.1.1.2 - Patient card,,2022-06-30
PT,Portugal,Post-Market,CA,1.2.1.1.3 – Information about the contact person,,2022-06-30
PT,Portugal,Post-Market,CA,"Recruiment Mode, Publicity Material, Questionnaires",1.2.1.2; 1.2.1.3; 1.2.1.4 respectively,2022-06-30
PT,Portugal,Post-Market,CA,1.2.2.1 - Declaration of the conditions of the center for carrying out the study,Site sustainability,2022-06-30
PT,Portugal,Post-Market,CA,1.2.2.2 - Declaration of the DM circuit,,2022-06-30
PT,Portugal,Post-Market,CA,1.2.3.1.1 – CV of the Coordinating Investigator,,2022-06-30
PT,Portugal,Post-Market,CA,1.2.3.1.2 – CV of Principal Investigators,,2022-06-30
PT,Portugal,Post-Market,CA,1.2.4.1 - Insurance and Indemnities,,2022-06-30
PT,Portugal,Post-Market,CA,1.2.4.2 - Compensation/payments to Participants,,2022-06-30
PT,Portugal,Post-Market,CA,1.2.4.3 - Contracts,,2022-06-30
PT,Portugal,Post-Market,CA,1.2.4.3.1 - Study centers,,2022-06-30
PT,Portugal,Post-Market,CA,2.1. – Clinical investigation plan + amandments,,2022-06-30
PT,Portugal,Post-Market,CA,2.2 - Synopsis ,in Portuguese,2022-06-30
PT,Portugal,Post-Market,CA,2.3.1 - Clinical Trials with the same DM(s),optional,2022-06-30
PT,Portugal,Post-Market,CA,2.3.2 - Scientific Assessment,if aplicable,2022-06-30
PT,Portugal,Post-Market,CA,2.3.3 - Ethical Assessment,if aplicable,2022-06-30
PT,Portugal,Post-Market,CA,3.1 – Investigator’s Brochure,In case of pre-market,2022-06-30
PT,Portugal,Post-Market,CA,3.2- IFU ,In case of PMCF ,2022-06-30
RO,Romania,Pre-Market,CA,Same as the CA documents,,2022-06-30
RO,Romania,Post-Market,CA,Same as the CA documents,,2022-06-30
RS,Unknown,Pre-Market,CA,Clinical trial protocol,,2022-06-30
RS,Unknown,Pre-Market,CA,IB,,2022-06-30
RS,Unknown,Pre-Market,CA,Synopsis ,In Serbian,2022-06-30
RS,Unknown,Pre-Market,CA,Proof of insurance,,2022-06-30
RS,Unknown,Pre-Market,CA,Procedures and documentation for obtaining ICF,In Serbian,2022-06-30
RS,Unknown,Pre-Market,CA,Procedures for the protection of vulnerable groups and individuals,,2022-06-30
RS,Unknown,Pre-Market,CA,Justification of the clinical trial from the ethical and scientific aspect,,2022-06-30
RS,Unknown,Pre-Market,CA,Appropriate benefit-risk assessment,,2022-06-30
RS,Unknown,Pre-Market,CA,"PI Cvs, GCPs",,2022-06-30
RS,Unknown,Pre-Market,CA,Site sustainability,,2022-06-30
RS,Unknown,Pre-Market,CA,Proof of fee payment,,2022-06-30
RS,Unknown,Pre-Market,CA,"Documentation (statement) regarding the conflict of interest of researchers in accordance with the law,",,2022-06-30
RS,Unknown,Pre-Market,CA,Documentation regarding the reimbursement of necessary costs,,2022-06-30
RS,Unknown,Pre-Market,CA,"Procedure regarding recruitment of respondents, including advertising, ie material with advertising elements",,2022-06-30
RS,Unknown,Post-Market,CA,Clinical trial protocol,,2022-06-30
RS,Unknown,Post-Market,CA,IB,,2022-06-30
RS,Unknown,Post-Market,CA,Synopsis ,In Serbian,2022-06-30
RS,Unknown,Post-Market,CA,Proof of insurance,,2022-06-30
RS,Unknown,Post-Market,CA,Procedures and documentation for obtaining ICF,In Serbian,2022-06-30
RS,Unknown,Post-Market,CA,Procedures for the protection of vulnerable groups and individuals,,2022-06-30
RS,Unknown,Post-Market,CA,Justification of the clinical trial from the ethical and scientific aspect,,2022-06-30
RS,Unknown,Post-Market,CA,Appropriate benefit-risk assessment,,2022-06-30
RS,Unknown,Post-Market,CA,"PI Cvs, GCPs",,2022-06-30
RS,Unknown,Post-Market,CA,Site sustainability,,2022-06-30
RS,Unknown,Post-Market,CA,Proof of fee payment,,2022-06-30
RS,Unknown,Post-Market,CA,"Documentation (statement) regarding the conflict of interest of researchers in accordance with the law,",,2022-06-30
RS,Unknown,Post-Market,CA,Documentation regarding the reimbursement of necessary costs,,2022-06-30
RS,Unknown,Post-Market,CA,"Procedure regarding recruitment of respondents, including advertising, ie material with advertising elements",,2022-06-30
SI,Slovenia,Pre-Market,CA,Application Form,electronic document in A4 format and in standard 10 pt font,2022-06-30
SI,Slovenia,Pre-Market,CA,1. Basic data on the application,Detail in the PDF guide,2022-06-30
SI,Slovenia,Pre-Market,CA,2. Introduction,,2022-06-30
SI,Slovenia,Pre-Market,CA,3. Participants,,2022-06-30
SI,Slovenia,Pre-Market,CA,4. Research plan,,2022-06-30
SI,Slovenia,Pre-Market,CA,5. Procedure,,2022-06-30
SI,Slovenia,Pre-Market,CA,6. Consent to participation,,2022-06-30
SI,Slovenia,Pre-Market,CA,7. Protection and confidentiality of data,,2022-06-30
SI,Slovenia,Pre-Market,CA,8. Assessment of possible risks and benefits of participation,,2022-06-30
SI,Slovenia,Pre-Market,CA,Informed Consent Form,More detail in the PDF guide,2022-06-30
SI,Slovenia,Pre-Market,CA,1. Introduction,,2022-06-30
SI,Slovenia,Pre-Market,CA,2. Obligation of the participants,,2022-06-30
SI,Slovenia,Pre-Market,CA,3. Compensation of the participants (if aplicable),,2022-06-30
SI,Slovenia,Pre-Market,CA,4. Risks and hazards of participants,,2022-06-30
SI,Slovenia,Pre-Market,CA,5. Benefits of paticipants,,2022-06-30
SI,Slovenia,Pre-Market,CA,6. Voluntary nature of participation,,2022-06-30
SI,Slovenia,Pre-Market,CA,7. Data information,,2022-06-30
SI,Slovenia,Pre-Market,CA,8. Contact information,,2022-06-30
SI,Slovenia,Post-Market,CA,Application Form,electronic document in A4 format and in standard 10 pt font,2022-06-30
SI,Slovenia,Post-Market,CA,1. Basic data on the application,Detail in the PDF guide,2022-06-30
SI,Slovenia,Post-Market,CA,2. Introduction,,2022-06-30
SI,Slovenia,Post-Market,CA,3. Participants,,2022-06-30
SI,Slovenia,Post-Market,CA,4. Research plan,,2022-06-30
SI,Slovenia,Post-Market,CA,5. Procedure,,2022-06-30
SI,Slovenia,Post-Market,CA,6. Consent to participation,,2022-06-30
SI,Slovenia,Post-Market,CA,7. Protection and confidentiality of data,,2022-06-30
SI,Slovenia,Post-Market,CA,8. Assessment of possible risks and benefits of participation,,2022-06-30
SI,Slovenia,Post-Market,CA,Informed Consent Form,More detail in the PDF guide,2022-06-30
SI,Slovenia,Post-Market,CA,1. Introduction,,2022-06-30
SI,Slovenia,Post-Market,CA,2. Obligation of the participants,,2022-06-30
SI,Slovenia,Post-Market,CA,3. Compensation of the participants (if aplicable),,2022-06-30
SI,Slovenia,Post-Market,CA,4. Risks and hazards of participants,,2022-06-30
SI,Slovenia,Post-Market,CA,5. Benefits of paticipants,,2022-06-30
SI,Slovenia,Post-Market,CA,6. Voluntary nature of participation,,2022-06-30
SI,Slovenia,Post-Market,CA,7. Data information,,2022-06-30
SI,Slovenia,Post-Market,CA,8. Contact information,,2022-06-30
SK,Slovakia (Slovak republic),Pre-Market,CA,Instruction ,"There is no direct communication between the Committee and the applicant (sponsor) following the new procedures, except the case of a clinical trial with CE marked medical device.     ",2022-06-30
SK,Slovakia (Slovak republic),Post-Market,CA,Instruction,Same documents as the CA submission ,2022-06-30
SE,Sweden,Pre-Market,CA,Instruction ,"For the ethical review, the first step is to fill in form 01 Description of the research project - medical devices. The form must be in Swedish and sent in as a searchable PDF. Then send all the documents to CA only. ",2022-06-30
SE,Sweden,Post-Market,CA,Instruction ,"For the ethical review, the first step is to fill in form 01 Description of the research project - medical devices. The form must be in Swedish and sent in as a searchable PDF. Then send all the documents to CA only. ",2022-06-30
UK,United Kingdom,Pre-Market,CA,Protocol,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Participant information sheet & ICF,Template: http://www.hra-decisiontools.org.uk/consent/examples.html ,2022-06-30
UK,United Kingdom,Pre-Market,CA,Data protection,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Organisation Information Document,Non-comercial & comercial version. For non-commercial studies it should be accompanied by a completed Schedule of Events.,2022-06-30
UK,United Kingdom,Pre-Market,CA,The Industry Costing Templates ,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Model Agreement,,2022-06-30
UK,United Kingdom,Pre-Market,CA,Funding ,,2022-06-30
UK,United Kingdom,Pre-Market,CA,"PI CVs, GCPs",,2022-06-30
UK,United Kingdom,Post-Market,CA,Protocol,,2022-06-30
UK,United Kingdom,Post-Market,CA,Participant information sheet & ICF,Template: http://www.hra-decisiontools.org.uk/consent/examples.html ,2022-06-30
UK,United Kingdom,Post-Market,CA,Data protection,,2022-06-30
UK,United Kingdom,Post-Market,CA,Organisation Information Document,Non-comercial & comercial version. For non-commercial studies it should be accompanied by a completed Schedule of Events.,2022-06-30
UK,United Kingdom,Post-Market,CA,The Industry Costing Templates ,,2022-06-30
UK,United Kingdom,Post-Market,CA,Model Agreement,,2022-06-30
UK,United Kingdom,Post-Market,CA,Funding ,,2022-06-30
UK,United Kingdom,Post-Market,CA,"PI CVs, GCPs",,2022-06-30
